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A little bit of history… 
 
Neuroblastoma (NB) was first described in 1864 by the German physicist Rudolf Virchow 
who observed an abdominal tumor mass in a child and called it, unaware of the origin of the 
tumor, a glioma1. About three decades later, in 1891, the German pathologist Felix 
Marchand reported that the tumor develops from the sympathetic nervous and the adrenal 
medulla. In 1910 James Homer Wright understood that the adrenal tumors were mainly 
composed of an identical cell type and realized that the tumor originates from the primitive 
neural cells -the neuroblasts-, and therefore named it neuroblastoma2.  
While tremendous progress has been made in treatment of childhood leukemia, success 
rates for high risk NB remain disappointing. It is a very complex and heterogeneous disease, 
on the one hand, NB accounts for disproportionate morbidity and mortality among the 
cancer of childhood while on the other hand, it is associated with one of the highest 
proportions of spontaneous and complete regression of all human cancers3. Typically, NB is 
subdivided in four stages based on the International NB Risk Group (INRG) Staging System. 
While stage L1 and L2 are localized or locoregional tumors with a favorable prognosis, 
patients with stage M have a metastatic disease and poor clinical outcome4. A specific 
subgroup of patients are those with stage MS, marked by metastases and the unusual 





NB: when development goes wrong 
 
NB is the most common extracranial pediatric solid tumor in children, accounting for 
approximately 7-10% of pediatric cancers and nearly 15% of all pediatric cancer deaths in 
patients younger than 15 years old3. Tumors develop from precursor cells of the sympatho-
adrenal lineage that arise from the neural crest, a transient component of the ectoderm that 
gives rise to diverse cell types, including the peripheral nervous system, the craniofacial 
skeleton and pigment cells5. Only progenitors from the sympathetic lineage acquire the 
genetic events that lead to neuroblastoma development, resulting in tumors that can arise 
anywhere along the sympathetic nervous system5.  
At the end of the third week and in the beginning of the fourth week of embryonal 
development, sympathoadrenal cells from the neural crest in the trunk region of the embryo 
follow a ventral migratory path from the neural crest and neural tube to give rise to various 
structures, including the sympathetic nervous system that develops from the fate-restricted 
sympatho-adrenal progenitor cells, the so-called neuroblasts5-7. Upon migration, these 
neuroblasts start to express a series of factors that further allow their differentiation into 
either the ganglionic or the chromaffin lineage. Together, these cells form the differentiated 
cells that populate the sympathetic ganglia, paraspinal ganglia and adrenal medulla. 
Interestingly, during normal sympathoadrenal development, expression of MYCN is high in 
the early post-migratory neural crest, where it regulates the ventral migration and expansion 
of the neural crest cells. Later on, MYCN protein levels gradually reduce during 
differentiation of the sympathetic neurons6.  
 
NB: an embryonal precancer 
 
Several clinical and experimental features link neuroblastoma development to defective 
embryogenesis and pathological neuroblast precancer. The idea of an embryonal origin was 
first supported by a study of De Preter et al8, They showed that gene expression profiles of 
human fetal adrenal neuroblasts are remarkably similar to those of NB tumors. Interestingly, 





life of the child, suggesting the existence of premalignant lesions and linking tumorigenesis 
to deregulated development6.  
 
The NB genomic landscape  
 
DNA copy number alterations 
 
The NB genomic landscape is marked predominantly by structural variants leading to 
amplifications, gains and losses while mutational burden is low. Therefore, NB can be 
considered as a so-called copy number driven cancer disease. The most frequent 
amplification is observed in more than 20% of the cases and encompasses the MYCN 
oncogene (V-Myc Avian Myelocytomatosis Viral Oncogene NB Derived Homolog)9,10. In 
addition to these amplicons which typically consist of 50 to 100 MYCN copies, large gains of 
the distal 2p-arm encompassing the MYCN locus are also frequently observed11. MYCN 
amplification was amongst the first identified prognostic genetic markers being associated 
with rapid disease progression and poor prognosis and was rapidly adopted into clinical 
practice12.  
MYCN is a member of the MYC proto-oncogene family that also includes MYC and MYCL. In 
addition to NB, MYCN amplification has been observed in a variety of other cancers with an 
embryonic and or a neuroendocrine origin like rhabdomyosarcoma, Wilms tumor and 
medulloblastoma13. MYCN protein functions through binding to the E-box sequences 
(CACGTG) in a heterodimeric complex with Max acting as a transcription factor that controls 
the expression of many target genes, which in turn regulate fundamental cellular processes 
including proliferation, cell growth, protein synthesis, metabolism, apoptosis and 
differentiation (Figure 1.1)14. Similar to MYC, MYCN plays an important role during 
embryonic development. Mutations in the human MYCN gene have been linked to birth 
defects, mouse embryos lacking MYCN die around E11.515 with MYCN being implicated in 






Figure 1.1: MYCN protein functions 
 
In addition to the frequently observed MYCN amplification, other loci have also been 
reported to be present in high copy numbers, however, with much lower incidence. Often, 
such rare amplifications occur together with MYCN amplifications and a recent study from 
Depuydt et al indicated that this marks a group of ultra-high risk patient with extremely poor 
outcome (Depuydt et al.          in preparation). LIN28B amplification and consequent elevated 
LIN28B expression levels cause down regulation of the let-7 family of miRNAs resulting in 
further increase of MYCN protein levels17. Additional amplifications occurring in NB have 
been reported including in ALK, MDM2, CDK4,…18-20  
Furthermore, typical patterns of large chromosomal gains and losses are observed in NB. 
First, numerical chromosomal imbalances in the absence of structural defects occur in 
localized L1 and L2 and special metastatic MS prognostic favorable cases, while structural 
imbalances including loss of 1p, loss of 11q and gain of 17q are confined to metastatic M 
cases with poor outcome21. Partial gain of chromosome arm 17q (gain of segment 17q23-
qter) is the most frequent abnormality of NB cells, present in more than 50% of cases and 
exclusively associated with poor prognosis. The principal mechanism underlying this partial 
gain is an unbalanced translocation with a variety of partner chromosomes, the most 
common translocation partner being chromosome 1p, resulting in the loss of 1p22. By cloning 
the translocation breakpoint our team could identify a new gene, NB breakpoint family 





NBPF1 and gives rise to two chimeric transcripts of NBPF1 sequences fused to sequences 
derived from chromosome 17. On chromosome 17, the translocation disrupts one of the 
isoforms of ACCN1, a potential glioma tumor suppressor gene23.  
Chromosome 17q driver genes in NB 
 
Partial gain of chromosome 17q is the most commonly observed genetic aberration in 
NB22,24. Because of its high frequency and its correlation with survival, it has long been 
assumed that one or several genes on 17q contribute to NB pathogenesis in a dosage 
dependent way. The specific genes and the molecular mechanisms responsible for 
development and progression of NB remain, however poorly understood. In a first attempt 
to gain better insights into the tumor process, several research groups tried to delineate the 
smallest region (SRO) of 17q gain24,25. This SRO which encompasses 17q23 till 17qter is still 
quite large and contains around 600 genes. Therefore other strategies to identify the culprit 
candidate genes had to be pursued. Interestingly, by performing DNA copy number analysis 
on 25 NB cell lines using comparative genomic hybridization, Saito-Ohara et al. identified a 
minimal region of gain at 17q2326 in one cell line. This region contains only 15 genes 
including BRIP1 and PPM1D, which encodes the phosphates WIP1, a negative regulator of 
p53 activity27. Downregulation of PPM1D using antisense oligonucleotides was shown to 
have a drastic effect on the growth of several NB cell lines26.  
BIRC5 or survivin, a member of the inhibitor of apoptosis (IAP) family, is a well-recognized 
oncogene in a variety of cancers and located on 17q25.3. Because of its well established role 
as an oncogene and its chromosomal location, one wondered if BIRC5 could function as an 
oncogene in NB as well. Indeed, BIRC5 is strongly overexpressed in human neuroblastoma 
tumors and correlates with poor survival outcome independent of 17q gain28. Likewise, 
silencing of BIRC5 in several NB cell lines resulted in mitotic catastrophy28. Another gene that 
has been put forward as a potential important NB 17q gene is NM23-H1 or NME129,30. Higher 
expression levels of NM23-H1 are correlated with a worse outcome in NB patients without 
MYCN amplification and in patients younger than 12 months of age30. It is postulated that 





Mutations/single base pair variants 
 
The most frequently recurring mutation in NB has been reported in ALK (anaplastic 
lymphoma kinase receptor tyrosine kinase) occurring in 8% of the cases and slightly more 
frequent in metastatic cases18,31. These activating mutations are mostly confined to the 
ATPase activating domain with two major hotspot mutations at positions R1275 and F1174 
and leading to constitutive activation of the receptor32. The discovery of these ALK 
mutations was a landmark for the development of precision oncology for NB patients and 
clinical trials with ALK inhibitors were initiated to evaluate their benefit for treating NB 
patients33,34. Further, studies investigated how ALK activation contributes to the tumor 
phenotype and unraveled downstream signaling offering further opportunities for 
drugging33. While ALK mutations where discovered through the study of familial cases35 (see 
below) and standard candidate gene sequencing18, more recently a comprehensive picture 
was achieved through whole exome and genome sequencing of primary tumors. In addition 
to the previously reported ALK mutations, this provided further insight into the mutational 
landscape of NB. Analysis of 87 whole NB genomes by the Versteeg team uncovered 
recurrent involvement of genes implicated in neuritogenesis and also identified a subset of 
cases showing genomic features of chromothripsis17. Further studies also revealed recurrent 
involvement of loss of function events in ARID1A and ARID1B, either through inactivating 
mutations or focal deletions in 9% of the NB cases36. ARID1A and ARID1B are members of 
the SWI/SNF transcriptional complex that is thought to regulate chromatin structure and 
gene expression. Of interest, mutations in the ARID1 genes are also correlated with a more 
aggressive NB phenotype36. Sequencing efforts also shed further light onto the genetic and 
clinical heterogeneity of NB. Indeed, inactivating ATRX mutations (both base pair 
substitutions and deletions) were observed in a significant portion of older children (> 
5years) and young adolescents37. ATRX mutations were mainly found in the minimal 
overlapping region of deletions involving exon 5 up to exon 10, which encodes a predicted 
nuclear-localization signal. Of particular interest, ATRX mutations were also associated with 
longer telomeres and activation of the ALT pathway in keeping with the finding that ATRX 
functions as a direct repressor of ALT promoting telomere lengthening38. This also fits with 
the mutually exclusive occurrence of ATRX defects with MYCN amplification as MYCN drives 





lengthening. In line with these observations, yet another sequencing study completed this 
picture showing that non MYCN amplified cases without ATRX mutations showed hTERT 
upregulation due to structural variants near the hTERT locus affecting hTERT expression 
levels39,40.  
Genetic predisposition to NB 
 
Familial NB is rare and only observed in 1% of the NB patients. They differ from sporadic 
tumors by the fact that they are diagnosed at earlier age41,42 and are frequently associated 
with other neural crest-derived developmental disorders such as Hirschsprung disease, 
congenital central hypoventilation syndrome and neurofibromatosis type I43. Due to the link 
of NB tumors with Hirschsprung disease and congenital central hypoventilation syndrome, 
PHOX2B was the first gene for which mutations were described that predispose the NB and 
was subsequently shown to be rarely targeted by somatic mutations. PHOX2B is a homeobox 
containing gene, which plays a crucial role during specification of noradrenergic cells44,45.  
Besides germline mutations, it has been shown that also single nucleotide polymorphisms 
(SNPs) can influence NB development. The Maris team conducted extensive genome wide 
association studies (GWAS) to identify particular SNPs predisposing to a higher risk of NB 
development. Through the Illumina HumanHap550 BeadChip assay, analysis of 1032 NB 
patients and 2043 controls gave a significant association between NB and the common 
minor alleles of three consecutive SNPs at chromosome 6p22 and containing the predicted 
genes FLJ22536 and FLJ44180 46. In a follow up study their analysis was restricted to 397 
high-risk cases and 2043 controls and detected a new significant association of six SNPs at 
2q35 within the BRCA1-associated RING domain-1 (BARD1) locus correlated with high-risk 
(Rs367816 OR= 1,82 p=5xE-14 and Rs643582 OR= 1,82 p= 2xE-15)47. The disease associated 
SNP correlates with the increase of an oncogenetically activated isoform of BARD1, BARD1β. 
BARD1β stabilizes Aurora kinase, which in turn will stabilize MYCN, resulting in a higher 
expression of MYCN.48. In a more comprehensive GWAS study using 2251 patients and 6097 
control samples a significant association in the LIM domain only 1 (LMO1) at 11p15.4 was 
identified. The signal was enriched in the subset of patients with the most aggressive form of 
disease. By analyzing DNA copy number alterations in 701 primary tumors they could also 




common causal SNP rs2168101 disrupts a GATA transcription factor binding site within a 








Zebrafish as a model organism 
 
Zebrafish, a tropical fish native to Southeast Asia, came in to the fore as a model organism in 
the early sixties for the study of developmental genetics. Its advantages for genetic studies 
are its high fecundity, the generation of transparent embryos that develop outside of the 
mother and the conservation of vertebrate organs, which allows comparison with humans51. 
Importantly, many cellular processes and developmental programs are conserved in 
vertebrates. The true usefulness of the model, however, was recognized as a result of 
several large forward genetic screens52,53 which identified mutants in almost every organ or 
cell, with most of them shared with mammals. This demonstrated for the first time that fish 
could be used to identify genetic mutants for almost any phenotype. 
However, like every model organism, zebrafish also possess some disadvantages. This 
species has undergone a partial genome duplication, so some genes present as two copies 
(approximately 20% of the genome). Next to that, their last shared ancestor with humans 
was 445 million years ago, so they are far more remote from humans than other animals 
such as rodents. Finally, not all genes are conserved in their genome, amongst others BRCA1, 
they are ectothermic (cold-blooded) and they have some anatomical differences compared 
to humans (lack of heart septation, limbs, lungs…)54. 
In the early years the fish were mainly used to study developmental processes and 
regeneration, though, in the beginning of this millennium it was noted that zebrafish can 
also be used to study cancer51,55. 
Zebrafish and its cancer models 
 
In the past it was already observed that zebrafish can develop cancer after mutagenic 
exposure or even spontaneously. In 2003, David Langenau proved for the first time that 
zebrafish also can develop cancer upon ectopic overexpression of a transgene56. He 
demonstrated that overexpression of m-MYC under the control of the recombinase 




lymphoblastic leukemia (T-ALL). Leukemia initiated in the thymuses but quickly spread 
throughout the complete body of the fish, which was clearly visualized since m-MYC was GFP 
tagged. Interestingly, it could be shown that these tumors resemble human cancers both on 
the histological and genomic levels57. Since then, zebrafish models have been described for a 
variety of cancers like melanoma, pancreatic cancer, malignant peripheral nerve sheath 
tumors (MPNST), Ewing sarcoma and also NB (Table 1.1)58. Upon overexpression of MYCN 
under the control of the dβh (dopamine β hydroxylase) promotor NB tumors could be 
observed at 9 weeks of age59 . In human cells, NB can be diagnosed by the presence of 
neurosecretory granules within the cytoplasm of the tumors cells. These neurosecretory 
granules were evident in the fish tumors, showing the relevance of NB zebrafish models in 
cancer research. Although the first results were pretty spectacular, the tumor penetrance 
stayed rather low. Only 22% of the MYCN transgenic fish developed tumors within half a 
year. In the past, it was already proven that activated ALK can collaborate in NB 
pathogenesis60 and therefore one wondered if overexpression of ALK in the MYCN 
background fish would accelerate NB development. This turned out to be true, coexpression 
of ALKF1174L with MYCN tripled the penetrance of NB and markedly accelerated tumor onset, 
with tumors starting to develop at 5 weeks of age59,61. Similar processes were observed for 
NF1 (neurofibromatosis type 1), loss of NF1 in tg(dβh:EGFP-MYCN) zebrafish resulted in an 
acceleration of NB onset. Moreover, it was shown that loss of NF1 results in aberrant 
expression of the RAS-MAPK pathway and this could be therapeutically inhibited using the 
MEK inhibitor trametinib62. 
Zebrafish, more than a cancer model… 
 
Besides the development of several cancer models in zebrafish, several technical revolutions 
took place in zebrafish. Because of its small size and its similarity to humans, 71% of the 
zebrafish proteins have a human orthologue, zebrafish are more and more used as a tool for 
drug discovery. Zebrafish are typically used to screen large compound libraries. Researchers 
will then specifically look for compounds that introduce a phenotype of their interest63. For 
example, in a phenotypic screen to identify FDA-approved drugs with activity against T-ALL, 
perphenazine was identified. Perphenazine, an antipsychotic drug, had a drastic effect on 





perphenazine exhibited suppressed cell growth64. For melanoma, transgenic mitf-BRAFV600E; 
p53-/- embryos were used to identify small molecule suppressors of the neural crest lineage. 
One class of compounds, inhibitors of dihydroorate dehydrogenase (DHODH), such as 
leflunomide, led to an almost complete retraction of neural crest development in zebrafish 
and a reduction in self-renewal of mammalian neural crest stem cells65. Recently, with the 
discovery of CRISPR-CAS a complete new revolution took place in the genome engineering 
field. In zebrafish, zinc finger nuclease (ZFN) technology and TALENs were already 
established techniques (Table 1.1), but because of its relative ease also CRISPR CAS was 
quickly introduced66. Moreover, also tissue specific CRISPR CAS quickly found his way into 
the zebrafish field67 . What’s more is that also our lab contributed to the integration of the 
CRISPR CAS technology in zebrafish. BATCH-GE, an easy to use bioinformatics tool for batch 
analysis of next generation sequencing (NGS) data was introduced68. BATCH-GE identifies 
and reports indel mutations and other precise genome editing events and calculates the 





Table 1.1: Transgenic models of cancers in zebrafish. Updated from58 
Cancer Oncogene Tumor suppressor gene  refs 
melanoma mitfa-BRAFV600E 
mitfa:EGFP:NRASQ61K 















mMYC x hsp70-cre 
rag2:NOTCH1 






B cell Leukemia TEL-AML1 (ETV6-RUNX1)  79 
Rhabdomyosarcoma rag2-KRASG12D  80 
Neuroblastoma dβh:EGFP-MYCN 




















Lipoma krt4:Hsa.myrAkt1  86 
Ewing’s sarcoma hsp70 or β-actin:EWSR1-FL1  87 
Liver fabp10:Lex1:EGFP x 
cryB:mCherry: LexA:EGFP-
krasG12V 









zmyod:MYCN  90 
Myeloproliferative 
neoplasms 




Pomc:pttg  92 













Replicative stress and cancer 
 
DNA replication stress 
 
DNA replication is a vital process of the living cell that guarantees precise duplication of the 
genetic information and subsequent transfer to the daughter cells. Although DNA replication 
is a highly controlled process, various perturbations originating from exogenous and 
endogenous sources can interfere with this process and can eventually lead to a slowing or a 
stalling replication fork, a phenomenon that is called replication stress95-97. There are 
multiple reasons why replicative stress can occur: 1) depletion of nucleotides required for 
replication or DNA repair; 2) interstrand lesions, 3) strongly bound proteins and complex 
stable DNA structures (e.g. G4 structures, see further) hampering progress of the replisome, 
4) RNA-DNA hybrids (R-loops) causing replication-transcription conflict etc… (Figure 1.2). 
Upon replication fork stalling, dormant origins of replications are activated to permit 
activation of replication. However, if two converging forks stall in regions lacking dormant 
regions, cells must restart at least one of these forks to ensure full genome duplication. 
Single strand DNA at the stalled replication forks will be coated by the ssDNA binding 
replication protein A (RPA). RPA-coated ssDNA stimulates the activation of the DNA damage-
checkpoint kinases ATR (and its obligatory partner ATRIP) and CHK1. Once activated, the 
ATR-CHK1 checkpoint response recruits accessory proteins, which will stabilize the halted 
fork and guarantees rapid resumption of DNA synthesis (Figure 1.3). When the amount of 
ssDNA surpasses the total of available RPA, the fork may collapse (defined as unloading of 








Figure 1.2: Mechanisms that can result in DNA replication stress. There are a number of 
mechanisms that can slow or stall DNA replication, including limiting nucleotides, DNA lesions, 
ribonucleotide incorporation, repetitive DNA elements, transcription complex and/or DNA hybrids, 
DNA secondary structures and fragile sites. Figure adapted from95  
 
 






Replication stress and cancer: the story of Jekyll and Hide 
 
Replicative stress drives tumor initiation: Cancer is the result of uncontrolled cell growth, 
and the accumulation of genomic alternations during cell division is a driving force for 
tumorigenesis. Subsequently, it is not surprising that replicative stress can contribute to 
tumorigenesis, given that excessive replication stress can result in DSB causing genomic 
instability (chromosomal rearrangements, deletions and chromosomal loss). In fact, 
replicative stress is a double edged sword, while on the one hand replicative stress can lead 
to genomic instability and in that way promote tumorigenesis, on the other hand replicative 
stress also represents an Achilles heel of the cancer cell where too much replicative stress 
can be fatal and may force the cell to go into apoptosis. For example, several oncogenes are 
known to cause replicative stress. MYC not only promotes cell growth by positively 
regulating the expression of many genes controlling the cell cycle (amongst others), it also 
represses anti-proliferative genes100,101. In addition to the transcriptional regulation, MYC 
also stimulates cell cycle progression by directly controlling replication initiation. It binds 
with the pre-replicative complex and will bind to DNA replication origins. Overexpression of 
MYC causes increased replication origin activity with subsequent DNA damage and 
checkpoint activation102,103. In vitro and in vivo experiments in MYC transgenic mice originally 
showed that transient MYC expression results in increased genomic instability and 
chromosomal aberrations that are typically observed in MYC-dependent human tumors and 
can contribute to cancer initiation and progression104.  
Cancer cells may become addicted to a replicative stress induced DNA damage response 
phenotype: It has been shown that excessive chronic replicative stress can hamper tumor 
growth and in embryonic stem cells accelerate aging105. In keeping with this finding, a mouse 
model overexpressing CHK1 through an extra copy was shown to be more prone to tumor 
development106. Furthermore, in T-ALL the Barrata team demonstrated the upregulation of 
CHK1, indicating that (hyper)activation of the ATR/CHK1 signaling pathway is required for 
survival and growth of these leukemic blast cells. Indeed, pharmacological inhibition or 
silencing of CHK1 using shRNAs impaired T-ALL proliferation and viability107,108. In NB, similar 
mechanisms have been observed. The MRN complex, a major sensor of DNA double 




replication stress109,110. In glioblastoma, it has been shown that TOP2β, an ATP dependent 
enzyme that catalyzes topological changes of DNA, is highly expressed in glioblastoma stem 
cells111. A recent paper showed that NEAT1 paraspeckle formation prevents accumulation of 
excessive DNA damage in cells undergoing replication stress. NEAT1 will preserve the 
genomic integrity of the tumor cell by modulating ATR signaling112. Interestingly, in mice, 
reduced levels of ATR found in a mouse model of the ATR-Seckel syndrome completely 
prevented the development of Myc-induced lymphomas or pancreatic tumors, both of which 
show abundant levels of replicative stress113. These examples show that replicative stress is a 
difficult balance for the cancer cell: replicative stress may act as initial initiator of the 
malignant process114, but sustained high levels of replication stress will impair the tumor 
cell’s viability. The fact that replication stress is less observed in normal cells but is a 
common feature of most cancer cells opens new possibilities for therapeutical interventions. 
For example, it has been shown that tumors deficient in BRCA2 like ovarian and breast 
cancer, can be specifically targeted using PARP inhibitors115. Since PARP1 is involved in the 
repair of single-strand breaks, upon inhibition, cells are forced to repair the break using the 
homologous recombination (HR) pathway. Nevertheless, tumors that are BRCA2-/- deficient 
cannot engage in the HR pathway so their only option will be to undergo apoptosis115. More 
recently, it was shown that cancer cells can be forced to go in apoptosis by incorporation of 
damaged dNTPs into the cancer cell. This can be reached by targeting MTH1, a protein that 
prevents the misincorporation of oxidized dNTPs during replication, using s-crizotinib. MTH1 
is dispensable in normal cells but since cancer usually move faster through the cell cycle, 
they often heavily rely on this protein116,117. Also molecular targeting of CHK1 has shown to 
be effective in different tumor types including NB107,108,118,119  
Replication stress as a new cancer hallmark 
 
In 2000, Hanahan and Weinberg described in their seminal paper, the hallmarks of cancer. 
They proposed that in general, cancer cells acquire six different hallmarks during their 
development. Typically, cancer cells will have a self-sufficiency in growth signals, they will be 
insensitive to growth inhibition signals, they will evade programmed cell death (apoptosis), 
limit their replication potential, sustain their angiogenesis and will invade tissues and 





subsequently an update of the hallmarks of cancer was warranted. In this update, four new 
cancer hallmarks were introduced and one of them was genomic instability121. While 
increased genomic instability in cancer is now a very well established concept as best 
exemplified by the rare cancer predisposition syndromes caused by germline loss of function 
mutations in DNA repair genes122, hyperactivation of the DNA repair machinery has thus far 
received much less attention, despite accumulating evidence that this phenotype indeed is 
present in various cancer types123. This is also illustrated and supported by this thesis in 
which we convincingly show that cancer cells are dependent for growth on high BRIP1 levels 
and also show that BRIP1 overexpression leads to accelerated tumor formation (Chapter 3). 
Moreover, in this thesis we also demonstrate that MYCN drives a FOXM1 activated DNA 
damage repair network that protects the tumor cells from excessive replicative stress 





BRIP1 (alias FANCJ or BACH1) 
 
BRIP1: the BRCA1 binding protein 
 
BRIP1, also known as FANCJ or BACH1, was first described by Cantor et al, as an interaction 
partner of BRCA1 (Breast Cancer Gene 1)124. The BRCA1 protein is a very large protein with 
only a few recognizable domains of which the RING domain and the BRCT domain are the 
most studied. Earlier, it was already shown that the RING domain of BRCA1 dimerizes with 
BARD1125. Since several clinical relevant point mutations were identified in the BRCT domain, 
it was important to identify the protein(s) that could bind to this domain. A GST fusion 
protein containing the BRCT motifs was used for a far western blot, and a 130kDa protein, 
BRIP1, was identified that binds to this tag. One mutation in BRIP1 (P1749R) led to greatly 
reduced binding, while the mutation M1775R completely abolished BRCA1 binding through 
the BRCT domain124. Radiation experiments in U20S osteosarcoma cells further showed a 
role for BRIP1 in DNA double strand break repair through BRCA1 binding, where BRCA1 
binding defective BRIP1 mutants showed a remarkable delay in DNA repair 6 hours after 
radiation124. In a follow-up study it was shown that the interaction between BRCA1 and 
BRIP1 depends on the phosphorylation status of BRIP1 and that this phosphorylation-
dependent interaction is required for DNA damage induced checkpoint control during the 
G2/M phase of the cell cycle126. Further in silico structural analysis revealed that BRIP1 also 
consists of 7 helicase domains, and that only the 3’ part of the BRIP1 protein binds to the 
BRCT domain (Figure 1.4). The helicase domains shows strong homology to the catalytic and 
nucleotide binding domains of known members of the DEAH helicases and it was shown that 
BRIP1 is a member of the DEAH helicase family124. 
 
 
Figure 1.4: The BRIP1 protein. BRIP1 consists of 7 helicase domains, a nuclear localization signal 






BRIP1 is a Fanconi anemia gene 
 
Fanconi anemia (FA) is an autosomal recessive disorder characterized by increased cancer 
susceptibility, congenital abnormalities, short stature and bone marrow failure causing 
anemia. FA patients are strongly predisposed to several types of cancer but are particularly 
prone to acute myeloid leukemia (AML)127. The FA cells show marked chromosomal 
instability and enhanced sensitivity to bifunctional alkylating agents that cross-link DNA (like 
mitomycin c, cisplatin) which is therefore used as diagnostic test. FA is a multigenic disorder, 
with at least twenty-one distinct complementation groups128,129 .The main function of the FA 
pathway seems to be the coordination of several distinct DNA repair pathways like, 
nucleotide excision repair (NER), translesion synthesis (TLS) and the homologous 
recombination pathway (HR).Originally thought to be involved in removing DNA crosslinks, 
more recent data have shown that the FA pathway also has an important role in the 




Figure 1.5: The FA complex. The pathway is activated when a replication fork stalls at an interstrand 
crosslink (ICL). The FA core complex binds to the stalled fork, leading to monoubiquitination and 
recruitment of the I and D2 proteins. The downstream FA proteins are recruited to DNA repair 




The FA proteins can typically be divided in two groups, whereby the majority of proteins 
belong to the core complex, which is a large multi-subunit ubiquitin ligase, the remainder of 
the proteins act downstream of this core complex. Upon DNA damage, the core complex will 
be recruited to the nucleus and bind to the stalled DNA replication fork. Subsequently, the 
core complex will then ubiquitinate FANCD2 and FANCI (Figure 1.5). Downstream of 
FANCD2, act FANCD1, FANCJ and FANCN. These proteins will then repair the DNA damage128 
(Figure 1.5). Interestingly, in 2005, BRIP1 and FANCJ were shown to be the same protein 133-
135. Moreover, in a following study it was shown that the BRCT-binding domain of BRIP1 is 
not required for its role in DNA crosslink repair or cell cycle arrest, showing that the BRIP1 
helicase acts independently of BRCA1 in Fanconi anemia for repairing DNA crosslink 136.  
 
BRIP1 as a potential tumor suppressor gene 
 
FA is a penetrant cancer susceptibility syndrome and several members of the complex are 
well known tumor suppressors (TSG), amongst others, BRCA2 and FANCN. Since BRIP1 is a 
member of the FA complex, researchers studied if germline BRIP1 mutations have an effect 
on tumor incidence. Indeed, heterozygous BRIP1 germline sequence variants were identified 
in familial breast, ovarian and prostate cancer124,137-139. However, a recent large scale case-
control study found no evidence of an association with breast cancer for 10 truncating 
variants of BRIP1. The upper 95% confidence limit excludes a twofold risk of breast cancer, 
often taken as the lower threshold for a moderate risk allele140. 
 
BRIP1 and interstrand crosslink (ICL) repair  
 
Interstrand DNA crosslinks can be formed as a natural product of metabolism or through 
induction of chemotherapeutic agents. In E. coli ICLs are repaired via a two-cycle repair 
mechanism. In the first round, incisions will be made on one strand on either side of the ICL, 
producing a gapped intermediate with the incised oligonucleotide attached to the intact 
strand. This gap is then filled by recombination repair or lesion bypass synthesis. In a final 
step, the remaining monoadduct is removed by the Nucleotide Excision Repair (NER) 





In the paper that described BRIP1 for the first time, it was shown that BRIP1 deficient cells 
are more sensitive for agents that introduce ICLs124. Since this acts independent of BRCA1136, 
Peng and colleagues used a two-step immunoaffinity strategy to identify new interaction 
partners of BRIP1. BRIP1 was found to exist in a protein complex with MutLα, a mismatch 
repair complex consisting of MLH1 and PMS1. Like BRIP1, MutLα was found to act 
downstream of FANCD2 monoubiquitination. BRIP1 interacts directly with MLH1 and 
independent of BRCA1. The interaction was mapped to the helicase domain of BRIP1, more 
specifically to lysine 141 and 142. Interestingly, disruption of the native MLH1/BRIP1 
interaction generates sensitivity to ICLs142. Although PMS1 does not directly associate with 
BRIP1, it stabilizes the BRIP1/MLH1 interaction. The functional role of BRIP1 in ICL processing 
remains largely unclear and controversial, in part, due to differences between experimental 
systems143. For instance, in DT40 chicken cells, loss of BRIP1 did not affect homologous 
recombination. This is probably due to the binding sites for MLH1 and BRCA1 that are not 
conserved in chicken BRIP1143.   
 
BRCA1 and its binding partner BRIP1 
 
BRCA1 is located on chromosome 17q21 and is best known for its tumor suppressor function 
in breast and ovarian cancer. Several functions have been attributed to BRCA1, but its role in 
dsDNA break repair is the most studied. One of the earliest indications that BRCA1 is 
involved in DNA repair was the observation that BRCA1 associates and co-localizes with 
RAD51 in nuclear foci in mitotic cells144. Co-localization with RAD51 has shown to be 
required for the strand invasion during HR (Figure 1.6)145. BRCA1 is also found to be 
associated with another DNA damage response protein, RAD50, which forms a tight complex 
with Mre11 and Nijmegen breakage syndrome gene 1. This complex of 
Mre11/Rad50/Nijmegen breakage syndrome gene 1 (MRN) is implicated in both homologous 
recombination and non-homologous end joining145 (NHEJ). 
BRIP1 binds to BRCA1 during HR and interestingly, when BRIP1 is uncoupled from BRCA1, the 
DNA damage response is altered. Specifically cells that express BRIP1S990A, a variant that 
cannot bind to BRCA1, are sensitive to dsDNA breaks and have a reduced RAD51-based 




BRCA1 and inhibits HR when unbound to BRCA1146, however, the exact role of BRIP1 in HR is 
not clear. Possibly, BRIP1 has an indirect role in HR as a ‘place-holder’ to prevent other 
proteins from disrupting HR, such as the anti-recombination helicases BLM or RTEL146.   
Although the mutation burden in NB patients is very low, an extremely rare homozygous 
nonsense germline mutation in BRCA1 (c.1151T>G/ p. Leu384Stop) has been described. The 


















Figure 1.6: Key steps of dsDNA break repair by HR. Figure adapted from145 
 
The helicase function of BRIP1 
 
The first germline mutations found in BRIP1, were located in the helicase domains indicating 
that these sequence changes disrupt its protein function. Later, it was shown that BRIP1 is 
both a DNA dependent ATPase and a 5’ to 3’ DNA helicase148 . A biochemical study showed 





on relatively short forked duplex substrates of 20 base pairs long149. BRIP1 is limited in its 
processivity, poorly unwinding substrates with duplexes of fifty base pairs or greater. 
Interestingly, BRIP1 is able to unravel forked duplex substrates of 47bp, but only in the 
presence of high concentrations of RPA150 .Next to that, a DNA junction is also required for 
BRIP1 to initiate unwinding of the adjacent duplex. BRIP1 is even able to unravel DNA-RNA 
hybrids (R-loops), however it fails on RNA-RNA hybrids. In C. elegans it was shown that dog-
1, the worm homologue of BRIP1, is required to maintain genetic stability of guanine rich 
DNA151. Mutations in dog-1 resulted in a mutant phenotype characterized by deletions 
throughout genomic DNA that was initiated at tracts of consecutive cG/dG bases. Here it 
was shown for the very first time that in addition of unwinding conventional duplex DNA 
substrates, BRIP1 also resolves alternate DNA structures like DNA G- quadruplexes. In this 
thesis we have explored the role of BRIP1 in NB through functional in vitro assays and in vivo 
modeling. Interestingly, in a parallel study, I observed a MYCN driven FOXM1 pathway 
activation as a dominant transcriptional perturbed signature during tumor formation 
(Chapter 4). FOXM1 is a well-known transcription factor controlling cell cycle and DNA 
damage repair and amongst others also regulates BRIP1 levels together with many other 





FOXM1: a central regulator of cell cycle and DNA damage 
 
FOXM1 in normal development and disease 
 
The forkhead box protein M1 (FOXM1), located on chromosome 12p33, belongs to the large 
family of the forkhead transcription factors. This forkhead family consists of more than 50 
members, and all of them have a central role during normal development and 
organogenesis. Three isoforms of FOXM1 protein have been previously described, FOXM1b 
and FOXM1c function as transcriptional activators while FOXM1a is transcriptionally 
inactive152. Several studies used in situ hybridization and immunohistochemistry to show 
that FOXM1 is expressed in many cell types during embryogenesis. These include precursor 
cells for liver and heart, smooth muscle and endothelial cells, pancreatic cells, thymocytes, 
precursors of granule neurons as well as epithelium and mesenchyme of the embryonic lung 
and intestine152-154. Because of its essential role in the embryogenesis, it is no surprise that 
knock out of FOXM1 in mouse is embryonic lethal155. Complete FOXM1 null mice die in utero 
18.5 days post coitus (dpc) due to multiple abnormalities in various organs including liver, 
lungs, blood vessels and heart. The other cell types in FOXM1-/- mice show no visible changes 
in either size or proliferation rates raising the possibility that FOXM1 has different functions 
according to the cell type156. 
 
FOXM1 functions as a transcription factor and mainly acts as a regulator of the cell cycle and 
DNA damage. FOXM1 preferentially binds to promotor regions with a consensus sequence 
“TAAACA”, although with lower affinity then his other family members of the forkhead 
proteins157. Its expression is restricted to proliferating cells and is both at the mRNA and 
protein level regulated by the cell cycle. The expression increases during the entry of the S-
phase, peaks during G2 and M and is diminished during mitotic exit158. Likewise, its 
transcriptional activity is tightly regulated throughout the cell cycle by multisite 
phosphorylation by different kinases, sumo proteins and its counteracting phosphatases, 
reaching its maximum activity in the G2 phase of the cell cycle159-161. More recently, it was 
shown that FOXM1 not only binds to “TAAACA” repeats but also to cell cycle genes 
homology region elements (CHR). In mammalian cells, these repeats control the 





that the dimerization partner of the DREAM complex (RB-like, E2F and multi-vulval class B) 
binds to these CHR sequences162-164. The DREAM complex is a protein complex responsible 
for the regulation of cell cycle dependent gene expression, its main function is to repress 
gene expression during quiescence (G0). One of the genes repressed by the complex is the 
proto-oncogene MYC162,165. In G0 p130 will prevent E2F4/5 from binding to its gene 
promotors, while entry into G1 will cause dissociation of p130 of the complex (Figure 1.7). 
During the G0 phase there is no expression of BMYB (MYBL2), however, during G1 BMYB will 
be expressed and will bind to MuvB during S phase to promote the expression of the key 
G2/M phase genes (CDK1, CCNB1). During G2 phase FOXM1 will then be recruited to further 




Figure 1.7 DREAM complex in quiescence and mitosis. Figure adapted from166 
 
Since FOXM1 has such an important role in cell proliferation and cell cycle progression, it is 
not surprising that increased expression of FOXM1 was detected in numerous cancer cell 
lines and human cancers167. One of the first studies detected upregulation of FOXM1 in basal 
cell carcinoma compared to normal skin samples168. Interestingly, in a meta-analysis of 




predictor of adverse patient outcome169. Up until today, overexpression of FOXM1 has been 
observed in more than 25 different tumor entities, including lung cancer, AML and NB170. In 
NB, FOXM1 serves as a critical activator of the tumorigenic properties of the aggressive 
forms of the NB cells. Next to that, FOXM1 has a direct connection with the pluripotency-
associated gene SOX2 in mediating the anchorage independent growth of the cells. NB cells 
with diminished FOXM1 expression undergo spontaneous differentiation with reduced levels 




Figure 1.8: cell cycle control by the DREAM complex. Figure adapted from162 
 
Molecular targeting of FOXM1 
 
Because of its involvement in cancer biology, FOXM1 was awarded the title “molecule of the 
year” in 2010. Since then several research groups tried to develop molecules that target 
FOXM1. Since FOXM1 is a transcription factor and therefore the compounds needs to 
translocate to the nucleus and bind to FOXM1 at the membrane, targeting is challenging. 
Despite this hurdle, several compounds that target FOXM1 have already been described, 
although most of them are assumed to affect FOXM1 indirectly. Siomycin A, thiostreptin and 





Gartel et al, hypothesized that proteasome inhibitors stabilize NRFM, which is a negative 
regulator of FOXM1. NRFM binds to FOXM1 and hence will inhibit the transcriptional activity 
of FOXM1. Since FOXM1 has a positive effect on its own expression through an 
autoregulation loop, expression of FOXM1 will decrease172,173. In addition to that, 
Balasubramanian et al. proposed an alternative mechanism, where thiostreptin binds to 
FOXM1 and consequently causes a blockage of the binding to the promoters of its target 
genes174 . Although proteasome inhibitors can be useful, such drugs act very broadly and 
unspecific thus requiring more specific compounds to target FOXM1.  
To achieve this goal, using an assay based on fluorescence polarization, a small molecule 
(FDI6) that disrupts the FOXM1-DNA interaction could be identified from a library consisting 
of 54211 molecules175. By using mass spectrometry, it was confirmed that FDI6 specifically 
binds to FOXM1. Treatment of MCF7 cells with FDI6 showed already after 3h a clear 
transcriptional effect of the known downstream targets of FOXM1 (like CDKN3, CENPA…)175. 
While these results are promising, recent data indicate that thus far, despite these reports 
and their validation, the effective " on target" effects of these drugs on FOXM1 are seriously 
questioned thus hampering reliable drugging studies to study e.g. dependency of tumor cells 
to FOXM1 and assess cancer types as possible targets for clinical FOXM1 drugging (Bollen, 
personal communication). 
The role of FOXM1 in the DNA damage response 
 
The first indications of a role for FOXM1 in DNA damage response came from an observation 
that FOXM1 deficient cells have an increased level of DNA damage176. Mouse embryonic 
fibroblasts (MEFs) derived from FOXM1 knockout mice showed high levels of γH2AX (a 
biomarker for DNA double stranded breaks) compared to wild type MEFs176. Those cells also 
had an increased number of TUNEL foci, suggesting a defect in DNA repair.  
When performing FOXM1 knock down experiments using siRNAs in osteosarcoma U2OS 
cells, high levels of spontaneous γH2AX foci were detected. This increase also correlated 
with decreased levels of the X-ray repair cross-complementing protein 1 (XRCC1) and 
decreased levels of the breast cancer-associated gene 2 (BRCA2), two genes involved in DNA 





In a cisplatin resistant breast cancer cell line, upregulation of FOXM1, BRCA2 and XRCC1 was 
observed upon cisplatin treatment, while downregulation of BRCA2 and XRCC1 was not 
observed prior to FOXM1 downregulation, suggesting that FOXM1 might regulate the 
expression of other genes involved in the DNA damage repair pathway177. In a follow up 
study, it was shown that double stranded breaks (through yH2AX staining) accumulate in 
breast cancer cells sensitive for epirubicin compared to breast cancer epirubicin resistant 
cells. Moreover, it was proven that FOXM1 overexpression was responsible for obtaining 
epirubicin resistance and it was demonstrated for the first time that FOXM1 is required for 
DNA double strand break (DSB) repair by homologous recombination (HR). In respect to that, 
BRIP1 (BRCA1 associated C-terminal helicase) was identified as a direct transcriptional target 
of FOXM1. Interestingly, ectopic overexpression of BRIP1 was able to partially rescue the 










G-quadruplex structures (also known as G4–DNA) are tertiary structures formed in nucleic 
acids by guanine rich sequences. Four guanine bases can associate through Hoogsteen 
hydrogen bonding to from a square planar structure called a guanine tetrad, and two or 




Figure 1.9: Structures of G-quadruplexes. G-quadruplexes contain tracts of three to four guanines 
and can be formed in DNA or RNA. The building blocks of G4 DNA are G-quartets that arise from the 
association of four guanines into a cyclic arrangement stabilized by Hoogsteen hydrogen bonding. 
The planar G-quartets pack on top of each other, forming four stranded helical structures. Figure 





Quadruplexes can be formed from one, two or four separate strands of DNA (or RNA) and 
can present a wide variety of topologies, which are in part a consequence of various possible 
combinations of strand directions, as well as variations in loop size and sequence179 (Figure 
1.9). Typically, the length of the nucleic acid sequences involved in the tetrad formation will 
determine how the quadruplex will fold180. 
In the early 1950’s it was already discovered that guanine-rich nucleic acids can self-
associate but their scientific value was at that moment neglected. Only after realizing that 
these G4-structures can be formed at the end of telomere regions and in this way will 
decrease the activity of the telomerase enzyme, researchers started to study these functions 
in depth. By using computational analysis of the human genome it was revealed that the 
human genome contains over 300 000 sequences that have the potential to form G-
quadruplexes, which further strengthens their possible important role in the human 
genome181. Next to that, it was found that the localization of G4-structures is not ad random, 
G4-DNA colocalizes with functional regions in the genome and furthermore are highly 
conserved between different species pinpointing to a selection pressure to maintain such 
sequences at specific genomic areas. Moreover, G4-DNA is also present in bacteria and in 
viruses180,182-185.  
The highest abundance of G4-structures is still in the telomeres, where it was shown that 
stabilization of the G4-structures using a G4 stabilizing compounds impairs proper telomerase 
activity and telomere shortening. It has been hypothesized that G-quadruplexes can 
sequester the 3’ end of the telomere. Indeed, in vivo data have indicated that parallel G-
quadruplexes can form at human telomeres, and that telomeres containing a G-quadruplex 
are a site of localization for human telomerase186.  
 
G4 structures regulate transcription and translation 
 
The finding that about 50% of the human genes contain a G4-structure near their promotor 
regions suggests a role for quadruplex structures in regulating gene expression. 
Fascinatingly, G4-structures are more frequently observed in oncogenes than in 
housekeeping or tumor suppressor genes181 . The first oncogene described with a G4-





its promotor resulted in aberrant transcription. Next to transcription, it has also been 
described that G-quadruplex structures are important to control translation. Andrew Wolfe 
and colleagues from our lab could show that genes dependent on transcription of eIF4A 
contain a 12-nucleotide pG4 signature that can form RNA G-quadruplex structures. eIF4A 
helps by the translation of mRNAs with long and complex UTRs, like MYC, NOTCH, BCL2, 
known oncogenes in T-ALL. Consequently, this paper showed for the first time that RNA G-
quadruplex structures are important for proper translation187. Blocking these RNA G-
quadruplex structures using silvestrol resulted in cell death in T-ALL cell lines and primary T-
ALL patient samples. 
 
G4 structures in replication and genome instability and the role of BRIP1  
 
Since single stranded DNA (ssDNA) is formed during DNA replication and G4-structures have 
the tendency to form during DNA replication, G4-structures can have a great impact on DNA 
replication. Upon creation, they have to be resolved as fast as possible, since otherwise this 
can lead to replication stress and eventually genome instability. By using Xenopus egg 
extracts to replicate exogenous G4 sequence on single-stranded DNA plasmids, it could be 
shown for the first time that DNA replication forks stall at G4 structures188. Mapping of the 
nascent strands at nucleotide resolution demonstrated that replication proceeded to within 
a few nucleotides from the G4. Furthermore, it has been shown that when cells face stable 
G-quadruplex structures, cells will activate dormant origins of DNA replication, in order to 
further control DNA replication189. If cells are unable to maintain processive DNA replication 
this will lead to the uncoupling of the DNA synthesis and recycling of the histones. In the 
original C. Elegans paper, mutations in dog-1, the homologue of BRIP1, resulted in a mutant 
phenotype characterized by deletions throughout genomic DNA that was initiated at tracts 
of consecutive cG/dG bases151. Since that report, several other observations were made 
confirming that BRIP1 has a role in unraveling G4-DNA structures. In Fanconi anemia patients 
with mutations in BRIP1, the loss of BRIP1 G4 unwinding function, correlates with the 
accumulation of large genomic deletions in the neighborhood of G4 sequences190. 
Furthermore, in human cells, BRIP1 deficiency resulted in a hypersensitivity to the G4 




were sensitive to TMS, suggesting that BRIP1 functions in G4 DNA metabolism independently 
from the classical FA pathway191. Finally, BRIP1 also has a G4 recognition site. Interestingly, 
the two lysine residues (K141/142) that are involved in G-quadruplex recognition also 
interact with MLH1 for repairing interstrand crosslinks192. 
So far, two different mechanisms for the unraveling of G4 DNA have been described. In C. 
Elegans loss of the BLM orthologue resulted in a massive increase in G-tract deletions, 
suggesting that BRIP1 and BLM may have an overlapping function in resolving G4 secondary 
structures193. Next to that, it was also observed that BRIP1 can interact with BLM helicase, 
further alluding that both of them function together in facilitating efficient DNA synthesis 
past the leading or lagging strand of G4 structures during replication194. In another in vitro 
study it was demonstrated that also WRN (Werner Helicase) smoothens DNA synthesis past 
a G4 structure in a DNA template195. Therefore, it was hypothesized that BLM and WRN 
would translocate on the opposite strand as BRIP1, and together these helicases collaborate 
to efficiently resolve the G4 structure so the unfolded G-rich sequence can be copied196 
(Figure 1.10). Another mechanism for the unraveling of G4 structures requires the 
involvement of REV-1 helicase. In this situation, REV1 will bind to the opposite strand of 
BRIP1 and together they will unwind the G4 structure197 (Figure 1.10). Up till today, it is 
largely unknown how BLM/WRN or REV1 exactly collaborate with BRIP1 for the unwinding of 
G4 structures196 .  
 
Targeting G4 structures 
 
The specific geometry of the G4 structure, with four grooves of unequal width coupled with 
an unusual electrostatic potential, is predicted to allow specific recognition by small 
compounds that bind within the grooves or intercalate with the DNA triple-helix. Indeed, 
several compounds, including porphyrins and anthraquinones, target G4 DNA and inhibit 
telomerase in vitro198. Up till today, several compounds have been described, each with their 
advantages and disadvantages. TMPYP4 tosylate has a strong affinity for G4 structures but 
turns out to be toxic for mice199. Similar effects were observed for pyridostatin200. BRACO-19 





Moreover, BRACO-19 was highly active on a broad range of tumors and reduced tumor size 
in average with 96% compared with untreated controls201 .   
 
Figure 1.10: Proposed model how BRIP1 resolves G4 structures. (A) BRIP1 acts together with BLM 
(or WRN) helicase to resolve the G quadruplex structure (B) BRIP1 interacts with REV1 at the site of 
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DNA is like a computer program, but far far more  
advanced than any software ever created 
~Bill Gates~ 
 










After decades of intensive research, the cancer entity NB remains an enigmatic disease and 
advances in unraveling the genome biology have been slow and challenging. This is reflected 
in the little amount of personalized therapeutic options and the slow progress in the survival 
changes of patients with aggressive disease. This, however, can partly be explained by the 
unique features of NBs. While in most other tumors several mutations can be identified, the 
mutational burden in NBs is low. Instead, several genomic aberrations are often identified, 
and this is why NB is typically regarded as a copy number disease. One of the irregularities 
that is typically observed is the gain of chromosome 17q, which is correlated with poor 
patient outcome. Despite thorough research, up till today, it is still unclear which genes on 
chromosome 17q contribute to the development of NB.  
Aim1: Unraveling the role of BRIP1 in NB development  
The first aim of my thesis was to follow up on a previous bio-informatics approach intended 
to identify candidate oncogenes on chromosome 17q (paper 1). This strategy identified 
BRIP1 as a potential driver gene in NB oncogenesis. BRIP1 is a member of the Fanconi 
anemia pathway and therefore in general considered as a tumor suppressor. To study its 
oncogenic capacities in NB, knock down experiments were performed in NB cell lines and a 
transgenic zebrafish model that overexpresses BRIP1 was developed.  
Aim2: Establishing a miRNA ESC signature score for the stratification of NB patients 
NB has been regarded as a developmental disorder, hence in this study, we wanted to 
deeper explore whether an ESC derived expression signature could capture a stemness 
phenotype in NB cells that is associated with therapy resistance (paper 2). FOXM1 was 
identified as a major driver and several compounds that target FOXM1 were therefore 
evaluated for use in NB in a follow-up study (paper 3).  
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Aim3: Identification of expressed repeat elements (EREs) in zebrafish to use for normalization 
in RT-qPCR.  
RT-qPCR is an elegant technique for performing gene expression analyses. Because of its 
relative ease and simplicity it is frequently applied. To correct for technically induced 
variation and thus measure true biological variation in samples, it is important to apply a 
good normalization strategy. Since in zebrafish, many commonly used reference genes are 
not always applicable because of their variability in expression levels, we evaluated a new 


























The important thing is not to stop questioning. 
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Neuroblastoma is the most common extracranial tumor in children and despite multimodal 
therapies the survival rates for children with aggressive neuroblastoma are still 
disappointingly low. Chromosome 17q gain is by far the most common DNA copy number 
alteration in high stage neuroblastoma. Due to the large size of the recurrently involved 
chromosome segments, the causal 17q drivers still remain to be identified.  
In this study, using an integrated bio-informatics approach, we identified the DNA helicase 
BRIP1 as top ranked candidate 17q driver gene. High expression of BRIP1 correlates with 
poor patient outcome. In neuroblastoma cell lines, we show that BRIP1 knock down 
significantly reduced cell viability and colony forming capacity. Next, overexpression of BRIP1 
in tg(dβh-MYCN-eGFP) transgenic zebrafish caused accelerated tumor formation. Given 
BRIP1‘s roles in preserving genome integrity, we show that knock down results in increased 
pRPA32 protein indicative for replication stress and that BRIP1 creates a cellular state what 
we call “replicative stress resistance”. BRIP1 is a downstream target of FOXM1 and moreover 
our data strongly suggest that FOXM1, a known important mediator of the MYCN driven 
oncogenic transformation of fetal neuroblasts controls the expression of several dosage 
sensitive 17q genes.  
In conclusion, we identified a new cooperative oncogene, BRIP1, involved in neuroblastoma 










Neuroblastoma is the most common extracranial tumor in children and is characterized by a 
variable clinical course and genetic heterogeneity1. Tumors are subdivided in four 
subclasses, stage L1 and L2 cases present with localized or locoregional disease with 
favorable prognosis, while patients with stage M have metastatic disease and poor clinical 
outcome. Stage MS cases have an unusual presentation with tumor spread to only the skin, 
liver, and/or bone marrow (less than 10% bone marrow involvement) in patients younger 
than 18 months and the majority of patients remarkably show regression with little or no 
treatment2. 
Recent sequencing efforts in neuroblastoma established a mutational landscape with a low 
mutational burden in comparison to other cancer types. In addition to the previously noted 
ALK activating mutations in only 10% of cases3,4, further rare mutations were noted in RAS-
pathway genes, epigenetic regulators and genes implicated in neuritogenesis5-8. Given these 
overall low mutation frequencies, selecting patients for precision treatment for molecular 
targets is challenging at present. In contrast to mutations, large copy number alterations 
(CNAs) in neuroblastoma are frequent and show remarkable recurrent patterns9,10. The 
metastatic tumor subtype almost invariably presents with partial 17q gain (often in 
combination with 1p loss, MYCN amplification and 2p-gains) which is also highly correlated 
with poor survival outcome10. Since gain of 17q is so frequently observed, it is assumed that 
one or several genes on 17q contribute to the development of the disease in a dosage 
dependent way. 
CNAs are a hallmark of cancer and can drive the expression of oncogenes or delete tumor 
suppressor genes and thus represent a source for therapeutic gene target discovery11. 
However, such CNAs typically harbor many genes hampering classical candidate gene 
approaches and require in vitro or in vivo screens or bio-informatics approaches to identify 
the culprit candidates. Of further note, using an in vivo screening approach, Mohankumar et 
al. identified eight new ependymoma oncogenes and 10 ependymoma tumor suppressor 
genes remarkably converging on a small number of cell functions contributing to the cellular 
state of the transformed cell12. Considering neuroblastoma as a CNA driven cancer, we 




data from primary human neuroblastomas in combination with transcriptome data from 
dynamic regulation of gene expression in Th-MYCN driven tumor formation.  
Using this approach, we identified BRIP1 (previously also called FANCJ or BACH1), located on 
17q23 within the commonly gained region on chromosome 17q, as top candidate 
cooperative driver. Subsequently we showed that forced overexpression in sympathetic 
progenitor cells caused accelerated MYCN driven tumor formation in a zebrafish model. 
BRIP1 is a downstream target of FOXM1, a transcription factor with key roles in cell cycle and 
the DNA damage pathway. Interestingly, also BRCA1, another FOXM1 downstream target, 
and many member of the Fanconi anemia pathway are highly upregulated during 
neuroblastoma development. We therefore propose that BRIP1 is a key play together with 
other FOXM1 targets in protecting neuroblastoma cells from excessive levels of replicative 
stress thus allowing smooth DNA replication and avoiding replication-transcription conflicts 
in these highly proliferative cancer cell.   
  




Material and methods: 
Neuroblastoma 17q gene ranking 
A subset of 356 patients with a 17q gain was selected from a large neuroblastoma cohort 
with aCGH data available (Depuydt et al, in preparation). Each gene presenting at least once 
in one of these 17q gains was ranked according to the sum logarithmic of the following 
ranked criteria: 1) percentile of 17q gains the gene is part of; 2) impact of high median gene 
expression on survival in the Fischer cohort7; and 3) the linear regression coefficient of the 
gene in our prior TH-MYCN model, indicating genes having a potential driving role in early 
neuroblastoma development14. 
 
17q dosage impact on BRIP1 
In order to validate an overall impact of 17q gain on BRIP1 expression, copy number data 
and paired expression data was retrieved from the NRC cohort for BRIP1. Copy number fold 
changes above 0.3 were considered as a BRIP1 gain. High and low expression were 
considered in respect to median expression in the cohort. 
 
Survival analysis  
Kaplan Meier analysis and Log Rank analysis was performed on the NRC neuroblastoma 
dataset (283 neuroblastoma patients) and the Fisher dataset7.  
 
Th-MYCN 
Experiments were performed as described by Beckers et al14. In brief, we sacrificed Th-
MYCN+/+ mice at one (n = 4) and two weeks (n = 4) after birth to harvest superior cervical 
and celiac ganglia containing foci of neuroblast hyperplasia, and 6-week old (n = 4) Th-
MYCN+/+ mice to dissect advanced neuroblastoma tumors, arisen from the neuroblast 
hyperplasia. Additionally, we dissected the superior cervical and celiac ganglia from Th-




expression changes during normal postnatal development of the sympathetic ganglia. We 




Neuroblastoma cell lines were grown as monolayer cultures at 37°C and 5% CO2 as in a 
humid atmosphere. The culture medium was RPMI 1640 (GIBCO, Life Technologies) 
containing 10% Fetal Calf Serum (FCS), 2mmol/l glutamine and the following antibiotics: 
Penicillin (1%), Kanamycin (1%) and Streptomycin (1%). Used cell lines were SH-SY5Y (MYCN 
non amplified, ALKF1174L mutant, partial 17q gain, high expression of BRIP1, FOXM1 and 
BRCA1) and IMR-32 (MYCN amplified, partial ALK amplification, partial 17q gain, high 
expression of BRIP1, FOXM1 and BRCA1).   
 
Lentiviral transduction BRIP1 
 
shRNA knock down for BRIP1 was achieved using MISSION shRNA clones TRCN0000049916 
and TRCN0000049917 (Sigma-Aldrich, St Louis, USA). Virus production was performed with 
15µg of plasmid in 3*106 HEK293TN cells using a calcium phosphate trans lentiviral 
packaging system, according to the protocol provided by the company (Thermofisher 
Scientific). Virus was harvested and concentrated with the PEG-it virus precipitation protocol 
(system Bioscience) and subsequently used for lentiviral transduction of IMR-32 and SH-SY5Y 
neuroblastoma cell lines.  
shRNA knock down for FOXM1 was achieved using MISSION shRNA clones 
(TRCN0000015544) in IMR-32 cells and was performed as described above. 
RT-qPCR,  Caspase glo, colony forming assays and cell cycle analysis 
 
Knock down after puromycin selection (0.5µg/ml for IMR-32 and 1µg/ml for SH-SY5Y) was 
confirmed using RT-qPCR. RNA isolation was performed using the protocol provided by the 
company (miRNEASY catalogue number 217004, Qiagen) followed with DNAse on column 




treatment (RNAse-free DNAse set catalogue number 79254, Qiagen). cDNA synthesis was 
executed with 500ng RNA input according to the protocol of the company (iScript catalogue 
number 170-8891, Bioké). RT-qPCR reactions were carried out in duplicate with a total 
volume of 5µl, including 2µl of cDNA, 2.5µl SsoAdvanced (172-5204, Bio-rad) and 0.25µl per 
primer pair (0.5µM). Following RT-qPCR primers were used for BRIP1 
(TGCTGTTTAATCCTCTGAGAATAG; CATGTTTAATCTGTTAGGAATCTGA), FOXM1 
(AGACACCCATTAAGGAAACG, TTTGTACTGGGCTGAAATCC) and reference genes 
HPRT1(TGACACTGGCAAAACAATGCA ,GGTCCTTTTCACCAGCAAGCT), 
YWHAZ(ACTTTTGGTACATTGTGGCTTCAA, CCGCCAGGACAAACCAGTAT). Cycling conditions 
were: 95°C (15s) – 60°C (15s) – 72°C (60s) with in total 44 cycli. Data were analyzed via 
qBasePlus software (Biogazelle).  
Caspase 3/7 was measured 24, 48 and 72h after seeding, using the caspase-glo 3/7 assay 
(Promega) according to the guidelines of the company. In brief, cells were seeded in a 96-
well plate with a density of 10 000 cells per well. Experiments were performed in triplicates 
(technical and biological) and GloMax luminometer was used for luminescence 
measurements.  
For the colony forming assays, cells were seeded, 2000 cells in a 6 cm dish, 72h upon 
lentiviral transduction to see the immediate effects upon BRIP1 knock down. 14 days after 
seeding cells were fixed with 0.5ml formaldehyde and subsequently stained with 0.005% 
crystal violet. Colonies were counted using the Image J software.  
Cell cycle analysis with PI Staining was performed according to the guidelines of the 
company (ab14083, Abcam). Cells were trypsinized and resuspended in 70% ice cold ethanol. 
Following several washing steps, cells were resuspended in PBS and RNAseA was added 
(final concentration 0.2mg/ml). After addition of PI the cells were immediately analyzed on 





DNA combing assay 
 
DNA fiber combing analysis was conducted using logarithmically growing IMR-32 and SH-
SY5Y cells as described by Schwab et al15. Cells were pulsed with iodo-deoxyuridine (IdU), 
and then pulsed with 5-chloro-2’-deoxyuridine thymidine (CldU) combined with hydroxyurea 
(HU). The cells were harvested and washed. A portion of the cells was lysed on a glass slide 
and the DNA fibers were straightened (combed) and fixed. Cells were subjected to 
immunofluorescence staining with mouse anti-bromodeoxyuridine (BrdU) (1/100, mouse 
anti-BrdU clone 44, 347580, BD Bioscience) or rat anti-BrdU (1/100, Rat monoclonal Anti-
BrdU antibody [BU1/75 5(ICR1)], ab6326, Abcam). The cells were washed with cold PBS, and 
incubated with Alexa 546-labeled anti-mouse (1/500, A21123, life technologies) and Alexa 
488 labeled anti-rat (1/1000, A21470, life technologies) at room temperature in the dark for 
1h.  
 
Western blotting and immunofluorescence 
 
Protein extraction was done via RIPA buffer and protein concentration was measured using 
the Lowry protein assay. Protein extracts were separated with SDS-PAGE, blotted on a 
nitrocellulose membrane and probed with antibodies against BRIP1 (1/1000 ; 4578S cell 
signaling), RPA32 (1/500, 14170S; cell signaling), pCHK1 (1/750, 2348S, cell signaling) and 
vinculin (1/10000, V9131, Sigma-Aldrich). Proteins were detected with HRP-conjugated goat 
anti mouse/rabbit IgG antibody (1/15000, sc2005, Bio-connect; 1/15000 A27036 thermo 
fisher scientific) and developed with ChemiDoc-it imaging system (UVP). 
For immunofluorescence, the cells were fixed in 4% paraformaldehyde and stained with anti-
y-H2AX (1/500) antibodies.  
  






Poly-A captured RNA library preparation was done on biological triplicates of BRIP1 
knockdown in IMR-32 and SH-SY5Y and control samples, using the TruSeq stranded mRNA kit 
LT. Concentration was measured via qPCR using the Kapa Library Quantification Kit (Illumina) 
and 1.4pM was loaded on a NextSeq 500. The NextSeq 500 High Output V2 75 cycles kit was 
used for single end sequencing to obtain approximately 20 million reads for every sample.  
Sample and read quality was checked with FastQC (v0.11.3). Reads were subsequently 
aligned to the human genome GRCh38 with STAR aligner (v2.5.2b). Final gene count values 
were obtained with RSEM (v1.2.31), which takes read mapping uncertainty into account. 
Counts were quantile normalized, followed by voom transformation and differential 
expression analysis with limma (R-package limma). Gene Set Enrichment Analysis (GSEA)16 
was performed on the list ordered according to differential expression statistic value (t) with 




Experiments were performed as described by Zhu et al17. Human BRIP1 was cloned behind 
the dβh-promotor and subsequently injected into the one cell stage of tg(dβh:EGFP-MYCN) 
offspring. These fish were screened every 2 weeks starting at 5 weeks post fertilization (wpf) 
for fluorescent EGFP expressing cell masses indicative of tumors. All experiments were 






Integrated bio-informatics analysis identifies BRIP1 as top dosage sensitive candidate 
cooperative driver oncogene in neuroblastoma 
In a first step of our analysis, we used CONEXIC, a computational framework that integrates 
CNAs and gene expression data to identify dosage sensitive driver genes18. Using this 
approach, the expected MYCN oncogene was amongst the top ranked drivers, validating the 
tool (Table 3.1). Next, we established a further ranking, which we will call ICON, for 17q 
genes based on (1) Percentile of 17q gains the gene is part of (2) gene expression profiles for 
each of the identified candidate drivers in different stages of tumor development in the Th-
MYCN mouse model14 (Figure 3.1A) and (3) impact of high median gene expression on 
survival in the Fischer cohort7 (Table 3.2) (Figure 3.1B-C). In the CONEXIC analysis BRIP1 was 
identified as the second highest gene, while in the ICON analysis BRIP1 was the top-ranked 
candidate. Highly elevated BRIP1 expression levels were correlated with poor prognosis in 
several data sets in keeping with the presumed oncogenic (cooperative) driver role for BRIP1 
(Figure 3.1B). Importantly, also in high risk patients for which often prognostic signatures 
poorly perform to discriminate survivors from children that died of disease, high BRIP1 
expression correlates with poor patient outcome (Figure 3.1C). Finally, further suggesting 
the oncogenic effect of BRIP1 overexpression in neuroblastoma cells, BRIP1 levels were 
amongst the highest in neuroblastoma only preceded by T-ALL (Figure 3.1D).  
 
Table 3.1: Top 10 dosage sensitive driver genes identified by CONEXIC 
gene Chromosomal location Deletion/gain 
MYCN 2p24.3 Amplification 
BRIP1 17q23.2 Gain 
DDX1 2p24.3 Gain 
EXO1 1q43 Gain 
VSP13D 1p36.22 Deletion 
MLL 11q23.3 Deletion 
EIF2C4 (AGO4) 1p34.3 Deletion 
HNRNPN 1q44 Gain 
DNAJC16 1p36.21 Deletion 
LCK 1p35.1 Deletion 
 




Table 3.2: Top 10 genes identified through ICON looking at % 17q gain, expression in the Th-MYCN 
mice and survival. 
Gene %gain survival Th-MCYN Combined 
BRIP1 78 0.28 1.019 21.668 
INTS2 78 0.09 0.53 21.56 
KPNA2 78 0.12 0.33 21.56 
BIRC5 77 0.35 1.24 21.53 
TK1 77 0.23 1.07 21.51 
PTRH2 78 0.23 0.25 21.5 
SMARCD2 78 0.02 0.44 21.48 
LIMD2 78 0.03 0.35 21.47 
PYCR1 77 0.21 0.57 21.46 
TSEN54 77 0.21 0.26 21.42 
 
BRIP1 knock down affects proliferation, apoptosis and cell cycle in neuroblastoma cells 
To understand the role of BRIP1 in the development of neuroblastoma, we first performed a 
series of functional tests. Knock down experiments with 2 different hairpins targeting BRIP1 
in neuroblastoma cell lines IMR-32 (MYCN amplified) and SH-SY5Y (MYCN non-amplified) 
were performed. For both shRNAs around 70% knock down was achieved (Figure 3.2A-B, 
Supplemental Figure 3.1A-B). Using the caspase-Glo assay we demonstrated increased 
apoptotic rates for the transduced cell lines versus controls after 72h (Figure 3.2C, 
Supplemental Figure 3.1C). Colony forming capacity of the BRIP1 depleted cells was 
dramatically reduced after BRIP1 knock down after 2 weeks (Figure 3.2D, Supplemental 
Figure 3.1D). Finally, cell cycle analysis showed a perturbed pattern with increased G1 phase 
arrested cells upon BRIP1 knock down as compared to the controls (Figure 3.2E, 
Supplemental Figure 3.1E). Collectively, these data indicate that neuroblastoma cells are 





Figure 3.1:BRIP1 as a new cooperative oncogene in neuroblastoma development. (A) Dynamic 
upregulation of Brip1 during tumor formation. Expression of Brip1 is upregulated during tumor 
formation as is seen in hyperplastic ganglia of Th-MYCN mice, starting to develop tumors from 6 
weeks after birth. In contrast, Brip1 is downregulated in wild type mice. Error bars represent the 
standard deviation of 4 biological replicates. (B) Kaplan-Meier survival plot of BRIP1 expression in 283 
neuroblastoma patients. Low expression of BRIP1 is significantly associated with better survival 
(p=3.3E-7). (C) Kaplan-Meier curve within the subset of neuroblastoma stage 4 tumors. Low 
expression of BRIP1 is correlated with better survival (p=0.03). (D) Expression of BRIP1 in the cancer 
cell line encyclopedia database. BRIP1 expression is the second highest in neurobastoma cell lines, 













Figure 3.2: BRIP1 knock down affects apoptosis, colony forming capacity and cell cycle in 
neuroblastoma cells. (A) SH-SY5Y cells were transduced with shRNA targeting BRIP1, followed by 
quantitative RT-PCR assessment of BRIP1 mRNA levels shown relative to the level in cells transduced 
with a scrambled shRNA. Error bars represent the standard error of mean (technical duplicates) (B) 
Corresponding western blot analysis of BRIP1 protein levels upon BRIP1 knock down. (C) Caspase glo 
assay in SH-SY5Y cells measuring caspase 3 activity upon BRIP1 knock down, error bars represent 
standard deviation of 3 biological replicates (D) Colony formation assays using SH-SY5Y cells depleted 
for BRIP1 compared to controls. Representative images of 3 independent experiments. (E) Cell cycle 
analysis in control cells and cells reduced for BRIP1 .Error bar represent standard deviation of 2 
biological replicates. 
 
High BRIP1 expression accelerates neuroblastoma development in zebrafish 
To corroborate our initial findings, we sought in vivo evidence for the oncogenic role of 
BRIP1 in MYCN driven neuroblastoma formation. To this end, we did forced overexpression 
of BRIP1 in MYCN overexpressing sympathetic progenitor cells in a stable tg(dβh:EGFP-




conditional tg(dβh:EGFP-MYCN) overexpressing zebrafish embryos and subsequently 
monitored tumor formation in two independent cohorts ( 10 and 8 tg(dβh:BRIP1) zebrafish, 
52 and 38 tg(dβh:EGFP-MYCN) zebrafish and 33 and 30 tg(dβh:EGFP-MYCN; dβh:BRIP1) 
zebrafish). While tg(dβh:EGFP-MYCN) transgenic fish develop tumors as of week eleven on17 
reaching a penetrance of 22%, double transgenic tg(dβh:EGFP-MYCN; dβh-BRIP1) fish 
develop the first tumors earlier at week 9 and reach a higher penetrance of 60% (Figure 
3.3A).The histopathology of the tumors was analyzed using H&E staining, and showed the 
expected large blue round cell typically observed in embryonal undifferentiated tumors 
(Figure 3.3B).  
 
Figure 3.3: Overexpression of dβh-BRIP1 into tg(dβh:EGFP-MYCN) results in the acceleration of 
neuroblastoma tumor formation and increases tumor penetrance. (A) Tumor free survival of 
tg(dβh:EGFP-MYCN), tg(dβh:BRIP1) and tg(dβh:EGFP-MYCN; dβh:BRIP1) zebrafish. (B) 
immunohistochemistry of tg(dβh:EGFP-MYCN; dβh:BRIP1) zebrafish.  
BRIP1 controls replication stress to maintain tumor genome integrity 
BRIP1 is one of the many Fanconi anemia genes acting in concert with other binding 
partners, including BRCA120. BRIP1 has been reported to be implicated in multiple functions 
related to replicative stress control including control of both CHK1 signaling and homologous 
DNA repair versus translesion DNA synthesis, promoting replication fork stability, recovery 
and restart, unwinding of stable G-quadruplex DNA structures and dissociation of RNA:DNA 
(R-loops) hybrids ahead of replication21.  
In order to confirm the need for elevated BRIP1 levels to control elevated replicative stress 
levels in rapidly dividing neuroblastoma cells, we evaluated the effect of reduced BRIP1 
levels on phosphorylated RPA (pRPA, S33) on western blot. RPA decorates ssDNA and pRPA 




is typically induced upon replicative stress as part of the activation of the DNA damage 
response ATR/CHK1 pathway and therefore considered as reliable marker for replicative 
stress induction. As expected, strongly upregulated levels of pRPA were observed following 
BRIP1 knock down in neuroblastoma cells on both western blots (Figure 3.4A). A second 
assay to monitor increased replicative stress is based on DNA combing and allows to 
visualize several aspects of DNA replication and fork dynamics. To explore this, DNA combing 
assays were performed in the presence and absence of hydroxy urea (HU), a well-known 
compound that induces replicative stress through blocking ribonucleotide reductase activity 
causing depletion of the nucleotide pool. Combined BRIP1 knock down and exposure to HU 
significantly increased replication fork stalling in keeping with the role of BRIP1 in control of 
replicative stress and dependency of neuroblastoma cells to high BRIP1 levels (Figure 3.4B-C, 
Supplementary Figure 3.2). Interestingly, reduced BRIP1 levels also induced increased pCHK1 
levels, suggesting that CHK1 signaling is still intact and elevated upon BRIP1 knock down 







Figure 3.4: BRIP1 controls replicative stress in the neuroblastoma tumor genome. (A) western blot 
analysis of phospho CHK1 (s345), phospho RPA32/RPA2 (S33), and γH2AX in SH-SY5Y and IMR-32 
cells upon BRIP1 knock down. (B) DNA combing analysis in IMR-32 cells with HU treatment. (C) 
Analysis of replication fork stalling in IMR-32 cells upon treatment of HU and BRIP1 knock down, p-
values were calculated using paired t-test. For each group, the median (horizontal line), the 
interquartile range (box), and the upper and lower range of the data (whiskers) are shown.  
BRIP1 promotes maintenance of genomic stability  
In cells undergoing high chronic increased levels of replicative stress stalled replication forks, 
the replisome dissociates from the fork leading to fork collapse. Collapsed forks with longer 
stretches of single strand DNA are prone to double strand breaks and causing genomic 
instability. While this might initially contribute to the tumor initiation process, chronic 
replicative stress may become detrimental for rapidly dividing cancer cells. To avoid this, 
cancer cells can become addicted to hyperactivated DNA damage response for their survival.  
In order to better understand the functional role of BRIP1 in neuroblastoma cells, we first 
tested yH2AX levels in IMR-32 cells undergoing increased replicative stress levels upon 




exposure to HU and indeed could demonstrate elevated levels of DNA damage (Figure 3.5A-
B). Next, we also performed RNA sequencing upon BRIP1 knock down in neuroblastoma cell 
lines IMR-32 and SH-SY5Y and observed cell cycle and DNA damage repair as major GO term 
for gene functions affected upon BRIP1 downregulation, in keeping with its presumed 
function in DNA repair (Figure 3.5C). 
Several recent studies have explored the protein interaction network at the DNA replication 
fork under normal conditions or replicative stress. From this, it became evident that a large 
number of proteins are implicated. In a comparison of proteins binding to nascent DNA at 
normal, stalled or collapsed forks, increased BRIP1 activity and interaction was detected at 
collapsed forks22. In a first step to explore the BRIP1 interactome in more detail in the 
context of neuroblastoma cells, IP-MS is currently ongoing.  
BRCA1 and other members of the FA- pathway are highly upregulated and possibly co-
regulated with BRIP1 
 
BRIP1 is known to interact with BRCA1 to execute several of the above mentioned functions. 
Correlation analysis using R2 for a large neuroblastoma tumor set (283 samples) showed 
very high level of correlation in expression levels for BRIP1 and BRCA1 (Figure 3.6A). In 
keeping with this finding, like BRIP1, BRCA1 is as expected also very high expressed in 
neuroblastoma (CCLE, R2, ..) and also linked to poor survival (Figure 3.6 B-C). In view of this 
observation, the important role of BRIP1 in replication fork protection and repair and the 
recently emerging role for the activated Fanconi anemia (FA) pathway in stabilizing 
replication forks and protection from collapse, we further investigated the expression levels 
of the FA-pathway in different stages of the neuroblastoma development. Overall, for 
all/most FA-genes, significant elevated to very high levels of expression were observed 
(Supplemental Figure 3.3) and almost all of them, except PALB2, correlated with poor 







Figure 3.5 BRIP1 maintains genome integrity. (A) Immunofluorescence of γH2AX in control IMR-32 
neuroblastoma cells with and without HU treatment and IMR-32 cells depleted for BRIP1 with and 
without treatment with HU. (B) Quantification of γH2AX spots described in (A), γH2AX is significantly 
increased in BRIP1 knock down cells treated with HU. The median (horizontal line), the interquartile 
range (box) and the upper and lower range of the data (whiskers) are shown (n= 2 biological 
replicates). (C) Important genesets to be found enriched upon knock down of BRIP1 in IMR-32 and 
SH-SY5Y cells. .  






Figure 3.6: BRCA1 is highly upregulated in neuroblastoma and is correlated with BRIP1. (A) 
correlation plot of BRCA1 and BRIP1. R-value= 0.92, P=value= 3E-116. (B) Dynamic upregulation of 
Brca1 during tumor formation. Expression of Brca1 is upregulated during tumor formation as is seen 
in hyperplastic ganglia of Th-MYCN mice, starting to develop tumors from 6 weeks after birth. In 
contrast, BRCA1 is downregulated in wild type mice. Error bars represent standard deviation of 4 
biological replicates. (C) Kaplan-Meier survival plot of 283 NB patients of BRCA1 expression. High 





CNAs act as transcriptional amplifiers for FOXM1 target genes including BRIP1 
 
While copy number changes have been shown to collectively install an oncogenic cellular 
state driving a hallmark phenotype in ependymoma, to what extent transcription factors 
controlling expression of these genes has not been addressed so far. First, we investigated 
whether BRIP1 was regulated by FOXM1 in neuroblastoma as BRIP1 was previously shown to 
be a bona fide target of this transcription factor23. To explore this we performed lentiviral 
knock down of FOXM1 in the neuroblastoma cell line IMR-32 and could indeed observe 
downregulation of BRIP1 upon FOXM1 depletion (Figure 3.7A-B). 
 
 
Figure 3.7: BRIP1 is a downstream target of FOXM1. (A) IMR-32 cells were transduced with shRNA 
targeting FOXM1, followed by quantitative RT-PCR assessment of FOXM1 and BRIP1 mRNA levels 
shown relative to the level in cells transduced with a scrambled shRNA. Error bars represent the 
standard error of mean (technical duplicates) (B) Corresponding western blot analysis of FOXM1 
levels (C) Venn diagram showing the overlap on 17q genes in the study of Olsen et al, Beke et al24, 
and Beckers et al14. genes included in triple overlap are BRCA1, TOP2A, BRIP1, BIRC5, SPAG5 and 
PRR11 
 
Next, we looked whether previously identified FOXM1 target genes were located on 17q and 
also generated a list of human 17q genes that were upregulated during Th-MYCN tumor 
formation in mice, either through an established mouse model14 or based on a novel neural 
crest derived model system (Olsen et al. Oncogene, accepted) and downregulated upon 
inhibition of FOXM124. Remarkably, several of the top regulated FOXM1 target genes 




including TOP2A, BIRC5 and BRCA1 were identified (Figure 3.7C). Further testing of dosage 
sensitivity for these genes is ongoing as well as their regulation through FOXM1 in 
neuroblastoma cells. Taken together, these data strongly suggest that FOXM1, a known 
important mediator of the MYCN driven oncogenic transformation of fetal neuroblasts 
(Olsen et al. Oncogene, accepted), controls the expression of several dosage sensitive 17q 
genes which are canonical target genes implicated in DNA repair (or more specifically 
replicative stress resistance) and G2/M transition located. In other words, one can envision a 
mechanism through which 17q gain acts as a genomic amplifier for FOXM1 target genes 
implicated in the MYCN/FOXM1 controlled process of neuroblastoma formation. Therefore, 






Chromosome 17q gain is the most frequent genetic alteration occurring in neuroblastoma 
while, except for ALK, mutations are rare in this tumor thus offering limited targets for 
precision oncology. Recent work in ependymoma has shown that large chromosomal 
imbalances can impact on gene expression levels of multiple oncogenes and tumor 
suppressor genes and that these broad genomic driven multiple gene dosage effects can 
impact on a given cellular state contributing to the tumor phenotype. 
Using a data mining driven approach, employing copy number and gene expression data 
from human neuroblastomas in combination with transcriptome data from dynamic 
regulation of gene expression in mouse neuroblastomas, we identified BRIP1, located on 
chromosome 17q23, as a cooperative oncogene in neuroblastoma oncogenesis. The gain-of 
function role for BRIP1 is unexpected given its well established tumor suppressor role as 
member of the Fanconi anemia complex and partner of the well-known BRCA1 tumor 
suppressor gene13,20,25,26. BRIP1 therefore joins the growing list of genes that can act both as 
oncogene and tumor suppressor depending on timing and cellular context, such as NOTCH1 
and EZH2 27,28. Reduction of BRIP1 levels in neuroblastoma cells drastically impacted on 
proliferation, increased apoptosis and blocked cell cycle progression. Forced overexpression 
of dβh-BRIP1 into the tg(dβh:EGFP-MYCN) zebrafish resulted in acceleration of tumor onset 
and an increase of tumor penetrance confirming its proposed role as an oncogene.  
The BRIP1 protein can interact with BRCA120 and, either in combination with BRCA1, or 
independently, acts to preserve the integrity of the genome. BRIP1 is required for 
homologous recombination-mediated double strand break repair, the execution of the 
G2/M cell cycle checkpoint29 and for normal progression through S phase by assisting in the 
resolution of stalled replication forks30, a phenomenon called replicative stress. Given that 
increased replicative stress can result in DNA damage and genome instability31, we 
wondered whether upregulation of BRIP1 is required to protect neuroblastoma genome 
integrity. Knock down of BRIP1 in neuroblastoma cells resulted in the upregulation of the 
ATR-CHK1 pathway, indicative for replicative stress. While contradictory at first sight, it has 
been shown that excessive replicative stress can be fatal for cancer cells. In fact, replicative 
stress is a double edged sword: on the one hand it can lead to genomic instability and 




promote tumorigenesis, while on the other hand replicative stress also represents an 
Achilles heel of the cancer cell since excessive replicative stress levels can be fatal to the 
cancer cell forcing it into apoptosis. In keeping with this latter aspect it is of interest that in 
mice an extra copy of CHK1 can predispose to cancer, which was shown to be associated 
with a reduction in the level of replicative stress induced by oncogenes32. By performing RNA 
sequencing upon BRIP1 knock down we observed enrichment for cell cycle and DNA 
replication, further strengthening our hypothesis that overexpression of BRIP1 is necessary 
to restrain replication stress observed by the tumor genome.  
In conclusion, we could show for the first time that BRIP1 is an important cooperative 
oncogene for the development of neuroblastoma. Moreover, we show that BRIP1 creates a 
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Supplementary Figure 3.1: BRIP1 knock down affects apoptosis, colony forming capacity and cell 
cycle in neuroblastoma cells. (A) IMR-32 cells were transduced with shRNA targeting BRIP1, followed 
by quantitative RT-PCR assessment of BRIP1 mRNA levels shown relative to the level in cells 
transduced with a scrambled shRNA. Error bars represent the standard error of mean (technical 
duplicates) (B) Western blot analysis of BRIP1 protein levels upon BRIP1 knock down. (C) Caspase glo 
assay in IMR-32 cells measuring caspase 3 activity upon BRIP1 knock down, error bars represent 
standard deviation of 3 biological replicates (D) Colony formation assays using IMR-32 cells depleted 
for BRIP1 compared to controls. Representative images of 3 independent experiments. (E) Cell cycle 
























Supplementary Figure 3.2: DNA combing analysis in SH-SY5Y cells with HU treatment 
 
 








Supplementary Figure 3.4: Kaplan-Meier curves of several members of the FA pathway.  
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Statement of translational relevance: 
Despite intensive multimodal therapies, survival rates for aggressive neuroblastoma patients 
are still disappointingly low. In this study, we wanted to deeper explore whether an ESC 
derived expression signature could capture a stemness phenotype in neuroblastoma cells 
that is associated with therapy resistance. An ESC miRNA signature could be defined that 
allows to discriminate patients with worse survival outcome in the global cohort of 
neuroblastoma patients, but most interestingly also in a subset of high-risk tumors, i.e. stage 
4 tumors without MYCN amplification. Analysis of the protein coding genes that are 
correlated with the ESC miRNA signature score in neuroblastoma patients, pointed at a 
FOXM1 driven cell cycle and DNA repair activation in therapy resistant tumors. These 







Purpose: Chemotherapy resistance is responsible for high mortality rates in high-risk 
neuroblastomas. MYCN is a major oncogenic driver in neuroblastoma controlling 
pluripotency genes including LIN28B. Therefore, we hypothesized that enhanced embryonic 
stem cell (ESC) gene regulatory programs could mark tumors with increased risk for therapy 
failure enabling the selection of patients for novel therapy approaches.    
Material and Methods: An ESC microRNA expression signature was established based on 
publically available data. In addition, an ESC mRNA signature was generated including the 
500 protein coding genes with the highest positive correlation with the miRNA ESC signature 
score in 200 neuroblastoma tumors. 
Results: High ESC miRNA signature scores were significantly correlated with poor 
neuroblastoma patient outcome in the global patient cohort and more importantly also 
within the subset of stage 4 tumors without MYCN amplification. In addition, in 
neuroblastoma tumors with MYCN amplification the ESC mRNA signature scores were 
significantly increased. Further data-mining identified FOXM1, member of the DREAM 
complex, as the major driver of the ESC mRNA signature score, controlling a large set of 
genes implicated in cell cycle control and DNA damage response. In addition, re-analysis of 
published data showed that MYCN transcriptionally activates FOXM1 in neuroblastoma cells.  
Conclusion: A novel ESC miRNA signature score stratifies neuroblastomas with poor 
prognosis, enabling the identification of tumors that are therapy resistant. The finding that 
this signature is strongly FOXM1 driven, warrants for drug screens and drug design targeted 
at FOXM1 or key components controlling this pathway.  
  
  





Childhood cancers have been regarded as developmental disorders and differ in many 
aspects from adult cancers. Typically, most childhood cancers show low mutational burden1 
and present with a very immature phenotype. It is assumed that embryonal tumors such as 
medulloblastoma, Wilms’ tumor, embryonal rhabdomyosarcoma and neuroblastoma arise 
from immature progenitor cells that still have a high level of stemness characteristics1. In 
these immature cells, disruption of normal early developmental pathways can cause 
differentiation arrest creating pre-malignant lesions that can subsequently develop to full 
blown tumors.  
Neuroblastomas that arise mainly in very young children with a median average age of 
diagnosis of 17 months1, are believed to emerge from cells of the developing adreno-
sympathetic nervous system1. In an earlier study, we provided support for this hypothesis 
through analysis of human fetal adrenal neuroblast transcriptomes which showed close 
similarity to malignant neuroblastoma gene expression profiles2. Also the few 
neuroblastoma driver genes that were identified so far, including MYCN, ALK, PHOX2B and 
LIN28B, are all involved in early stages of the sympathetic nervous system development3-5 
with both LIN28B and MYCN implicated as major drivers of stemness6. Novel therapies 
targeting these neuroblastoma driver genes such as ALK inhibitors and inhibitors of the 
BRD4-MYCN-promotor interaction are already emerging7. While these developments are 
promising, outcome of high-risk neuroblastoma patients is still disappointingly low and 
insights into therapy resistance mechanisms and new venues for targeting these resistant 
cells are needed. High treatment failure rates could possibly be explained by the stemness 
features of cancer initiating cells, including enhanced DNA repair capacity8. Therefore, 
scrutinizing in more detail the stemness features of pediatric cancers may provide new 
insights into therapy resistance and may also offer novel targets for therapeutic 
intervention.  
In this study, we explored the stemness features of neuroblastoma tumor cells using an in 
silico analysis starting from a normal embryonal stem cell driven miRNA signature. This 
approach was based on three important concepts. First, several hallmark characteristics of 
stem cells, including the capacity to self-renewal and differentiation are mimicked in the 




normal stem cells and cancer stem cells9. Secondly, miRNAs are key players in the tight 
control of (stem) cell fate10. These small non-coding RNA molecules play a crucial role in 
stem cell pluripotency, control of self-renewal, lineage-specific differentiation, and cell 
reprogramming10. The miRNA pathway has been shown to be crucial in embryonic 
development and in embryonic stem cells (ESCs), as shown by Dicer knockout analysis11. 
Specific patterns of miRNAs have been reported to be expressed only in ESCs and in early 
phases of embryonic development. Hence, regulatory networks tightly controlled by miRNAs 
can be assumed to play important roles in normal and cancer stem cell biology. Third, miRNA 
expression patterns can distinguish tumor types and tissue types better than mRNA 
expression patterns12. From these observations we anticipated that miRNAs could act as a 
proxy to capture stem cell features in neuroblastoma cells. 
To this end, we used an unique in silico approach to investigate the stemness characteristics 
in neuroblastoma tumor cells and obtained three important results: (1) a 60 miRNA ESC 
signature could discriminate patients with poor survival within a subset of the high-risk 
neuroblastoma patients; (2) biological function enrichment analysis on the coding genes 
correlated with the miRNA ESC signature score in neuroblastoma revealed increased DNA 
repair mechanisms in tumors with high stem cell capabilities driven by the FOXM1 
transcription factor, which was further confirmed by FOXM1 knock down experiments; (3) 
analysis of transcriptional changes after FOXM1 knock-down in neuroblastoma cells and re-
analysis of published datasets strongly supports the contribution of FOXM1 to the MYCN 
driven tumor and stemness phenotype of neuroblastoma cells. In view of these findings, our 
data should fuel renewed efforts for identifying novel on target compounds to block FOXM1 
activation in high-risk neuroblastomas. 
  




Materials & Methods 
Re-analysis of publically available datasets 
In this study, we reanalyzed several published expression datasets: miRNA expression data 
of different embryonal stem cell lines and differentiated tissue (GSE34199)13-17, 2) miRNA 
expression data of 200 neuroblastoma tumor samples18, 3) matching mRNA expression 
profiling data of the same 200 samples (GEO85047), 4) RNA sequencing data of 498 
neuroblastoma tumors (GSE62564, GSE49711)19, 5) miRNA and mRNA expression data of the 
Th-MYCN neuroblastoma progression model (E-MTAB-2618)20, 6) miRNA expression data of 
the different neuroblastoma mouse models5,20, 7) mRNA expression data of the shMYCN 
knock-down system (GSE39218)21 , 8) mRNA expression data of JQ1 and OTX015 treated 
neuroblastoma cell lines (GSE43392, E-MTAB-3672)22,23, 9) mRNA expression profiling data 
of siFOXM1 treated breast cancer cells (GSE55204, GSE25741)24,25 and shFOXM1 treated 
glioma cells (GSE63963)26, 10) mRNA expression profiling data of glioma, prostate, and 
breast cancer cell lines after pharmacological inhibition of FOXM1 with siomycin A and FDI-6 
(GSE50227, GSE36531, GSE58626)27-29, 11) data of the cancer cell line encyclopedia30 and 12) 
medulloblastoma mRNA expression data (GSE30530)31. The R-package GEOquery and 
ArrayExpress were used to download the publically available (normalized) data directly into 
the R-environment. ChIP-seq data of MYCN and H3K27ac in BE2C, Kelly, NGP and SHEP21N 
were downloaded from ArrayExpress (E-GEOD-80154) and converted to bigwig files to 
visualize the ChIP tracks in IGV. 
 
miRNA profiling of normal neuroblasts and human embryonic stem cell lines  
miRNA expression of 8 embryonal stem cell lines32 and 7 normal neuroblast samples2 was 
profiled and normalized as previously described33 (data will be submitted to a data 
repository).  
 
Data-mining and statistical analysis 
We performed signature score analysis on both mRNA and miRNA expression data using a 
rank-scoring algorithm as described in34. In brief, for each tumor sample (mRNA or miRNA) 




expressing gene). Next, rank scores for the signature genes were summed for each sample 
generating a signature score.  
Correlation of the score with survival was tested using Kaplan-Meier plots and log-rank 
analysis by grouping the samples in 2 equal groups (score above or below the median value) 
(R-survival package). Comparison of signature scores or expression between groups of 
samples was done using the parametric t-test or non-parametric Mann-Whitney test (R-base 
package). Signature score and gene expression correlation analysis was performed using 
Pearson correlation analysis (R-base package). Gene set enrichment analysis (GSEA)35 was 
performed using the version 5.2 geneset catalogue. Multivariate logistic regression analysis 
was performed on a subset of samples including only the patients that died of disease or 
survived for at least 3 years after diagnosis. 
 
FOXM1 gene silencing through shRNA knock-down and verification of knock down by RT-
qPCR and Western Blot analysis 
ShRNA knock down for FOXM1 was achieved using MISSION shRNA (Sigma) 
TRCN0000015544. Viral production was performed with 15 µg of plasmid in 3 million 
HEK293TN cells using the calcium phosphate trans-lentiviral packaging system, according to 
the protocol provided by the manufacturer (Lifetechnologies). The viral particles were 
concentrated using the PEG-it virus precipitation protocol (System Biosciences) and 
afterwards transduced in the neuroblastoma cell line IMR-32.  
24h after transduction the medium was refreshed and cells were selected with puromycin 
(0.5µg/ml). Cells were harvested for RNA 96h after transduction. RNA isolation was 
performed using the miRNeasy micro kit, according to the guidelines of the company 
(Qiagen, catalogue number 217084), including DNAse treatment on column (RNAse-free 
DNAse set, Qiagen, catalogue number 79254). cDNA synthesis was carried out using 500ng 
of RNA with the iScript cDNA synthesis kit (Bio-Rad, catalogue number 170-8891). RT-qPCR 
primers for FOXM1 (AGACACCCATTAAGGAAACG,TTTGTACTGGGCTGAAATCC) and reference 
genes HPRT1(TGACACTGGCAAAACAATGCA ,GGTCCTTTTCACCAGCAAGCT), 
YWHAZ(ACTTTTGGTACATTGTGGCTTCAA, CCGCCAGGACAAACCAGTAT), SDHA 
(TGGGAACAAGAGGGCATCTG, CCACCACTGCATCAAATTCATG) were designed using primerXL 
(www.primerXL.org). RT-qPCR reactions were performed in duplicate in a total volume of 
5µl, including 2µl of cDNA and 3µl of ssAdvanced SYBR Green qPCR mastermix (Bio-Rad). 




Cycling conditions were 95°C (15s) – 60°C (15s) – 72°C (60s) and 44 cycli. Data analysis was 
performed using the qBasePlus software (Biogazelle). Protein extraction was done via RIPA 
buffer and protein concentration was measured using the Lowry protein assay. Protein 
extracts were separated with SDS-PAGE, blotted on a nitrocellulose membrane and probed 
with antibodies against FOXM1 (1/1000 ; 5436S cell signaling),  and β-actin (1/10000, A2228, 
Sigma-Aldrich). Proteins were detected with HRP-conjugated goat anti rabbit IgG antibody ( 
1/15000, A27036, thermos fisher scientific) and developed with ChemiDoc-it imaging system 
(UVP). 
 
Differential gene expression analysis by RNA sequencing of FOXM1 knock-down in 
neuroblastoma cells 
Poly-A captured RNA library preparation was done on biological triplicates of FOXM1 knock-
down and control samples, using the TruSeq stranded mRNA kit LT. Concentration was 
measured via qPCR using the Kapa Library Quantification Kit (Illumina) and 1.4pM was 
loaded on a NextSeq 500. The NextSeq 500 High Output V2 75 cycles kit was used for single 
end sequencing to obtain approximately 20 million reads for every sample.  
Sample and read quality was checked with FastQC (v0.11.3). Reads were subsequently 
aligned to the human genome GRCh38 with STAR aligner (v2.5.2b). Final gene count values 
were obtained with RSEM (v1.2.31), which takes read mapping uncertainty into account. 
Counts were normalized with the TMM method (R-package edgeR), followed by voom 
transformation and differential expression analysis with limma (R-package limma). Gene Set 
Enrichment Analysis (GSEA)35 was performed on the list ordered according to differential 
expression statistic value (t). 
 
ChIP-sequencing of MYCN and H3K27ac in neuroblastoma cell line CLB-GA  
In addition to published ChIP-seq data, we also performed ChIP-seq in the non-MYCN 
amplified CLB-GA cell line. Chromatine immunoprecipitation for MYCN and H3K27ac was 
done in fifty million CLB-GA cells using 12.5 µg of MYCN-specific (Santa-Cruz, B8.4.B, sc-
53993) and H3K27ac-specific (Abcam, ab4729) antibody according the ChIP-protocol 
described in36. DNA was subsequently adaptor ligated and amplified using the NebNext Ultra 
DNA Library Prep Kit (E7370S) and sequenced on the NextSeq500 using the NextSeq 500 




genome using Bowtie2 and peakcalling was performed using MACS2. Bigwig files were 
generated to visualize the ChIP-seq tracks in IGV. 
 
Information of the used neuroblastoma cell lines 
The CLB-GA cell line was obtained from the lab of Valerie Combaret (Lyon, France). 
The IMR-32 cell line was obtained from the lab of Rogier Versteeg (Amsterdam, The 
Netherlands). 
All cell lines in our laboratory were screened upon arrival with the MycoAlert Detection 
Assay (cat nr. LT07-318, Lonza) and immediately expanded for freezing in order to assure 
Mycoplasma free cells as a stock. Routinely monthly random screenings were done, which 
were each time completely negative. 
Both cell lines used in the paper (CLB-GA and IMR-32) were brought in culture, and passaged 
two times before starting the experiments. Cells were kept in culture for maximum 20 
passages. After that: new cells were brought in culture. 
All cell lines were routinely STR genotyped, to confirm the authenticity of the cell lines.  
 
  





Figure 4.1: Identification of a ESC miRNA signature score that stratifies neuroblastoma patients 
within a subset of high-stage neuroblastoma. 
(A)ESC miRNA signature scores in embryonic stem cells (ESC line)32, neuroblastoma tumors (NB 
tumors)18 and normal neuroblasts2. (B) ESC miRNA signature scores in MYCN non amplified 
neuroblastoma tumors (MNA) compared to MYCN amplified neuroblastoma tumors (MA). (C-D) 
Kaplan-Meier and log rank analysis of 200 neuroblastoma patients with a high or low ESC miRNA 
signature score (using median as cut-off). DOD, dead of disease. (E-F) Kaplan-Meier and log rank 
analysis within the subset of stage 4 MYCN non amplified patients. (H) ESC miRNA signature score 
during tumor development in Th-MYCN transgenic mice. (G) ESC miRNA signature scores for MYCN, 
ALKF1174L and Lin28b neuroblastoma mice tumors and their normal counterparts (adrenal gland and 
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Embryonic stem cell miRNA signature score analysis identifies patients with poor survival 
within a subset of high-risk neuroblastoma patients 
In order to evaluate the stem cell features of neuroblastoma cells, we first established a 
robust miRNA embryonic stem cell (ESC) signature based on literature data. To this end, 
gene lists were retrieved from 4 published studies reporting on differential miRNA 
expression analysis of ESCs versus more differentiated cells (Supplemental Table 4.1)14-17. 
miRNA genes that were listed in at least 2 of the publications were included in the ESC 
signature (Table 4.1). A gene cluster with a well-known role in ESCs is the miR-302/367 
cluster, of which all components are present in the signature. Using signature score analysis 
(see M&M), we could validate the signature in an independent dataset of ESCs with high 
miRNA signature scores for the ESC samples compared to differentiated somatic tissue 
(Supplemental Figure 4.1)13 . 
Next, we generated miRNA expression data of ESCs32, normal neuroblasts and 
neuroblastoma tumor samples2,18. We confirmed high scores for the ESCs compared to those 
of neuroblastoma tumor samples (Figure 4.1A). The normal counterpart cells, i.e. the normal 
neuroblasts isolated from fetal adrenal glands, have ESC miRNA signature scores in the 
higher range of the scores identified in neuroblastoma tumors samples. The large dynamic 
range of scores in neuroblastoma tumors warranted us to evaluate whether this 
heterogeneous expression pattern could reflect tumor characteristics including MYCN status 
and patient survival. Indeed, tumors presenting with MYCN amplification have significantly 
higher signature scores than MYCN single copy tumors (t-test, p-value = 4.282e-05) (Figure 
4.1B). In addition, Kaplan-Meier and log-rank analysis pointed at a significant correlation 
with survival, i.e. patients with higher scores have lower survival chances (Figure 4.1C and 
D). According to multivariate logistic regression analysis, this significant correlation is 
independent of the currently used risk markers, i.e. MYCN status, stage (stage 4 versus other 
stage) and age at diagnosis (below or above 1 year) (Odds’ ratio 3.08, p=2.16E-2 for the 
signature score using median cut-off). More specifically, MYCN single copy stage 4 tumors 
with high ESC miRNA signature scores (above the median score) have extremely low survival 
probability, i.e. 19.6% overall survival at 5 years after diagnosis (95% confidence interval: 
7.52%-51.1%) versus 69.5% (52.6%-91.9%) in tumors with low ESC miRNA signature score 




(Figure 4.1E and F). This relation cannot be generalized to all other tumor types as we could 
not confirm this link in published miRNA expression datasets of ovarian cancer and 
glioblastoma (data not shown)37,38.  
Taken together, these data indicate that highly aggressive neuroblastoma cells in patients 
with ultra-high risk and very poor survival are enriched for a stemness ESC derived gene 
signature and that application of this signature could be helpful for early detection of 
patients for novel treatment strategies. 
 
The ESC miRNA signature score is dynamically upregulated during MYCN driven tumor 
formation and is highest in the ALKF1174L/MYCN double transgenic mice 
In the tyrosine hydroxylase (Th)-MYCN neuroblastoma mouse model, a clear increase in the 
ESC miRNA signature score during tumor development from pre-neoplastic lesions in the 
ganglia at week 1 and 2 to full-blown tumors at week 6 after birth is observed (Figure 
4.1H)20. Furthermore, Th-MYCN- and also dβh-iCre; LSL- ALKF1174L-, and dβh-iCre; LSL-LIN28B-
driven mice tumors are characterized by higher ESC miRNA signature scores compared to 
normal adrenal gland (Figure.4.1G)5,39. Interestingly, the ESC miRNA signature score in 
double transgenic mice tumors (MYCN/ALKF1174L) is significantly higher than in ALKF1174L-
driven tumors (significant difference with p=1.905E-2), in concordance with shorter time to 
tumor appearance and thus more tumor aggressiveness in double transgenic mice compared 
to ALKF1174L-transgenic mice. 
Overall, these results generated in human and mice tumors show that a high ESC signature 
score is linked to higher tumor aggressiveness, in keeping with the observed poor survival in 
patients with tumors with high miRNA ESC score. 
 
The ESC mRNA gene signature in neuroblastoma is highly enriched for FOXM1 driven cell 
cycle and DNA repair genes 
In order to understand the underlying biological functions of high miRNA ESC signature 
scores in aggressive neuroblastoma, GSEA analysis was performed on the list of coding genes 
ranked according to degree of expression correlation with the ESC miRNA signature score in 
200 NB tumor samples (Supplemental Table 4.2). Gene sets enriched among the positively 
correlated genes are involved in chromatin remodeling, response to DNA damage (double 




c2-cgp) and MYC and E2F targeting (MSigDB Hallmark genesets) (adjusted p-values < 0.001) 
(Figure 4.2A-F). These findings were confirmed by DAVID-gene ontology analysis on the top 
500 correlated genes showing enrichment for cell cycle and DNA damage/repair genes 
(functional annotation clustering: first cluster with cell cycle gene sets has enrichment score 
of 41.93, second cluster with DNA damage/repair functional classes has enrichment score of 
29.52, cut-off for significance is 1.3).  
We also performed motif enrichment analysis using iRegulon40 to identify transcription 
factors that drive the expression of the top 500 correlated genes, further referred to as the 
ESC mRNA signature (Supplemental Table 4.3)40. Within the top 10 most significantly 
enriched transcription factors, several members of the DREAM complex, which has an 
important role in transcriptional repression of cell cycle genes and maintaining quiescence, 
are present including E2F, MYBL2 and FOXM141. DREAM-complex members FOXM1, MYBL2, 
E2F1/2/3/7/8 and LIN9 are all part of the top 500 correlated gene list. Furthermore, FOXM1 
is a transcription factor known to target several genes involved in the enriched DNA repair 
pathway, including EXO1, BRIP1, BRCA1, BRCA2, CHEK1, BUB1B, XRCC2 and RAD51AP1k, all 
of which are in the top 50 of the ESC mRNA signature42. Also part of the gene list is CENPF 
which is a known FOXM1 target that cooperates with FOXM1 as recently shown for prostate 
cancer43, as well as MELK, CDK6, PLK1 which are all described as regulators of FOXM1 
phosphorylation44. Interestingly, the expression of 3 of these genes i.e. MELK, MYBL2 and 
PLK1 is remarkably highly correlated with FOXM1 expression levels in 200 neuroblastoma 
tumors (correlation coefficients > 0.9) suggesting a very tight co-regulated transcriptional 
control.  
Collectively, our findings support that the ESC mRNA gene signature in neuroblastoma is 
driven by the FOXM1 transcription factor. 
 
Differentially expressed genes after FOXM1 knock-down in neuroblastoma cells are enriched 
for mRNA ESC signature genes  
To provide more direct proof that the ESC mRNA gene signature is strongly FOXM1 driven, 
we next performed FOXM1 knock down and gene expression profiling in the neuroblastoma 
cell line IMR-32 with high ESC mRNA signature score and high FOXM1 expression levels 
(Supplemental Figure 4.2A-B). Subsequent GSEA of down regulated genes after FOXM1 
knock-down revealed enrichment for gene sets related to DNA repair, E2F and MYC targeting 




(MSigDB Hallmark genesets) and in cell cycle and double strand break repair (MSigDB c5-
gobp) (Figure 4.3A-D). Of further note, the 500 ESC geneset is also significantly enriched in 
the IMR-32 FOXM1 knock-down data (Figure 4.3E) (GSEA-analysis, adjusted p-values < 
0.001). This is also confirmed in other cancer types where the ESC mRNA signature goes 
down upon chemical and pharmacological FOXM1 knock-down (Supplemental Figure 4.3)27-
29.  
Taken together, this experimental analysis further supports the data-mining driven 
observation that the ESC mRNA gene signature in neuroblastoma cells is enriched for genes 
that are transcriptionally regulated by FOXM1.   
 
The ESC mRNA signature is activated by MYCN activity in vivo and in vitro in keeping with 
direct binding of MYCN to the FOXM1 promotor  
Previous work has provided evidence for a coordinated role of MYC and FOXM1 in 
controlling normal S-phase progression in mouse embryonic stem cells45. Furthermore, as 
indicated above, we observed MYC target gene enrichment in the genes downregulated 
upon FOXM1 knock-down. Therefore, we further investigated MYCN controlled regulation of 
the FOXM1 gene signature. To this end, we reanalyzed data of several in vitro MYCN 
neuroblastoma model systems. In these datasets, we observed decreased ESC mRNA 
signature scores and FOXM1 expression levels upon MYCN knock-down and pharmacological 
MYCN activity inhibition using JQ1 and OTX015 (Figure 4.4A, B, C)21-23. Also in the Th-MYCN 
mouse model an increase in ESC mRNA signature score and FOXM1 expression is observed 
upon MYCN driven development from hyperplastic ganglia towards full-blown 
neuroblastoma tumors (Figure 4.4D)20. Remarkably, the expression of all top 50 correlated 
genes from the ESC mRNA signature, including FOXM1, increases upon Th-MYCN driven 
neuroblastoma development (Figure 4.4D). In neuroblastoma tumors, the ESC mRNA 
signature score is significantly higher in tumors with versus without MYCN amplification 
(both in the global cohort and the subset of stage 4 tumors) (Figure 4.4E-F, Supplemental 
Figure 4.4I-J). Interestingly, higher ESC mRNA signature scores were also observed in other 
tumor cell lines with MYCN amplification (Supplemental Figure 4.5)31. Altogether, these data 
point to an important role of MYCN in the regulation of the ESC signature genes. Therefore, 
we further investigated the possible binding of MYCN to the FOXM1 promotor region using 




FOXM1 promotor. In these data, direct binding of MYCN on the FOXM1 promotor is clearly 
observed in both MYCN amplified and non-amplified cell lines. Clear peaks for H3K27ac were 
also observed showing open chromatin and active transcription (Figure 4.4H) (E-GEOD-
80154).  
Furthermore, similar as to the ESC miRNA signature, ESC mRNA signature scores are related 
to survival in a global cohort of neuroblastoma tumors, but also in a subgroup of stage 4 
tumors without MYCN amplification (Supplemental Figure 4.4A-D). This observation is 
confirmed in an independent dataset of 498 neuroblastoma tumors  (Supplemental Figure 
4.4E-H)19.  
Altogether, these data point at a MYCN activated FOXM1 driven ESC signature that is 
prognostic in neuroblastoma tumors. 
 
 
Figure 4.2: Important genesets found to be enriched using gene set enrichment analysis (GSEA) on 
the list of coding genes ranked according to the degree of correlation with the ESC miRNA 
signature score in 200 neuroblastoma patient samples. NES= normalized enrichment score, FDR= 
false discovery rate. 
A B C
D E F
NES= 3,92; FDR < 0.001 NES= 3,42; FDR < 0.001 NES= 3,22; FDR < 0.001
NES= 3,59; FDR < 0.001 NES= 3,19; FDR < 0.001 NES= 1,98; FDR < 0.001





Figure 4.3: Important genesets found to be enriched using gene set enrichment analysis (GSEA) 




E FNES= 3,12; FDR < 0.001 NES= 2,70; FDR < 0.001 NES= 1,69; FDR =0.008975






Figure 4.4: Association between MYCN and FOXM1 in the ESC mRNA signature score 
(A) ESC mRNA signature score upon lentiviral knock-down of MYCN in IMR-32 neuroblastoma cells, 
(B) upon pharmacological inhibition of MYCN with JQ1 in SKNBE(2)-C and Kelly neuroblastoma cells, 
(C) after inhibition of MYCN with JQ1 and OTX015 in IMR5 neuroblastoma cells, and (D) during tumor 
development in Th-MYCN mouse model. (E-F) ESC mRNA signature score in neuroblastoma patient 
samples with and without MYCN amplification in a global cohort (F) and in stage 4 neuroblastoma 
patient samples. (G) Heatmap of expression of the top 50 correlated genes of the ESC mRNA 
signature in the Th-MYCN mouse model. (H) ChIP-seq profiles of H3K27ac and MYCN transcription 
factor binding at the FOXM1 promotor in both MYCN amplified (NGP, BE2C, KELLY) and MYCN non 
amplified (CLB-GA, qval=6.3x10-5) cell lines as well as the SHEP21N cell line with induced MYCN 
expression. 





Several studies have shown that a stem cell like (stemness) gene signature may offer 
prognostic information in certain cancer types9. Given that (1) neuroblastoma is an 
embryonal neural crest derived tumor, (2) MYCN is critical for the maintenance of embryonic 
stem cell-derived neural crest stem cells6 and (3) LIN28B, a known stem cell marker, acts as 
oncogene in neuroblastoma5, we wanted to deeper explore whether an ESC derived miRNA 
signature could capture a stemness phenotype in neuroblastoma cells and be applied as tool 
to select neuroblastoma patients with therapy resistant tumors. Having established an ESC 
derived miRNA prognostic classifier, we could indeed show that within the subgroup of high-
risk patients we were able to predict with high confidence patients that would not benefit 
from current treatment regimes. Indeed, neuroblastoma patients with high ESC miRNA 
signature score have higher chance to die of disease or relapse as illustrated in Kaplan-Meier 
analyses. The survival difference for tumors with different scores is most striking for high-
stage neuroblastoma tumors without MYCN amplification, while all tumors with MYCN 
amplification have higher ESC miRNA signature scores. Such a prognostic classifier could be 
helpful to identify patients in a subset of high-stage cases that would be eligible for phase I 
trials for novel compounds in so-called basket trials46.  
 
To understand the key drivers of the high ESC signature scores and possible cause of therapy 
resistance mechanisms in ultra-high risk neuroblastomas and as a prelude to drugging the 
stemness phenotype in neuroblastoma, we applied a unique data mining approach. We 
established a mRNA signature derived from correlation analysis of the initial ESC miRNA 
signature score with gene expression profiling data in a large set of primary human 
neuroblastomas. Functional and motif enrichment analysis on the top 500 correlated genes, 
further referred to as the ESC mRNA signature, pointed at a central role of transcription 
factor FOXM1 and several other members of the DREAM complex, including MYBL2, E2F and 
LIN9 in controlling the stem cell characteristics of aggressive neuroblastoma cells, by keeping 
cell cycle and DNA repair mechanisms in check. The DREAM complex has an important role 
in cell cycle by coordinating the shift from quiescence to proliferation41. When cells exit the 
G0 phase, FOXM1 and MYBL2 are recruited to promote mitotic gene expression41 thereby 




have been described to have a role in sustaining the self-renewal capacity of pluripotent 
stem cells45, as also shown in neuroblastoma cells47. This regulatory axis may represent an 
important novel therapeutic vulnerability for neuroblastoma. These results are also in 
keeping with earlier findings of Wang et al47 who reported FOXM1 regulation of Sox2 and 
Bmi1 expression impacting on renewal of neural progenitor cells and survival of 
neuroblastoma cells.  
 
Next, we further explored the link between MYCN and stemness6 through further analysis of 
several MYCN model systems, i.e. the dynamic regulated transcriptome of Th-MYCN driven 
mouse neuroblastomas20, neuroblastoma cell lines upon knock-down of MYCN expression21 
and upon pharmacological inhibition of MYCN activity22,23. Collectively, these data 
demonstrate correlation of high ESC mRNA signature scores with high MYCN activity, further 
confirmed by high ESC mRNA signature scores in MYCN amplified human tumors compared 
to non-MYCN amplified cases. Not unexpectedly, a subset of high-stage neuroblastoma 
tumors without MYCN amplification also have elevated ESC signature scores, in keeping with 
high MYC activity in these cells. Similar as with the miRNA ESC signature, this subgroup of 
neuroblastoma patients is marked by very poor survival outcome.  
Interestingly, our ESC mRNA gene set shows a very strong overlap with a gene set recently 
derived by Olsen et al. (Oncogene, accepted) in a novel mouse neural crest derived 
neuroblastoma model. In brief, this study describes how mouse neural crest cells are grown 
and differentiated in vitro to generate sympathetic progenitor cells. Subsequently, these 
cells were transduced with MYCN and injected into mice to generate neuroblastomas. 
Analysis of the MYCN upregulated genes in the resulting mouse tumors also showed a strong 
enrichment of FOXM1 controlled genes involved in cell cycle and DNA damage control 
corroborating our data in human primary tumors and the Th-MYCN mouse model.  
 
In a huge pan-cancer dataset including ~18.000 tumors, a FOXM1 regulatory network was 
identified as a major predictor of adverse outcome across different tumor entities48, 
matching with the described link of FOXM1 with cancer therapy resistance49 and its role in 
DNA damage control42 as described in stem cells and tumors like neuroblastoma. In the light 
of the studies that pinpoint FOXM1 as an important pan-cancer gene, several labs are 
undertaken efforts to identify drugs that target FOXM1. The past years, several drugs 




presumed to target FOXM1 activity have been reported but so far none of these drugs has 
been successfully applied in the clinic, possibly due to off target and or insufficient on target 
effects of these drugs. While our study warrants further drug screening for more potent and 
specific FOXM1 inhibitors29, it is also of great interest that the FOXM1 upstream regulatory 
kinase MELK is also highly expressed, suggesting that this could act as a good candidate drug 
target for ultra-high risk neuroblastoma patients. Recently, a specific MELK inhibitor, MELK-
T1 was tested, and could represent a useful novel drug for improving survival rates for 
children with neuroblastoma50. 
 
Similar as our ESC miRNA signature, Ittai Ben-Porath et al. 9 has built an ESC mRNA signature 
consisting of 380 genes overexpressed in ESC according to 5 or more out of 20 profiling 
studies and could show an associated to prognosis in breast cancer. We tested this mRNA 
signature in expression data of 200 neuroblastoma tumors and could show correlation of 
high signature score with worse outcome in the global patient cohort, but not in the subset 
of high-stage tumors without MYCN amplification (data not shown). Moreover, the signature 
did not contain the DREAM complex genes, FOXM1, MYBL2, LIN9 and E2F. Thus, our unique 
approach did not only lead to more strong and robust prognostic signatures, but also 
revealed some putative mechanism of therapy resistance in neuroblastoma. 
 
In conclusion, by (re)analysis of published and unpublished expression profiling data, we 
could unravel a MYC(N)-FOXM1-ESC signaling axis that is active in therapy resistant 
neuroblastoma tumors and that unveils new vulnerable nodes for targeted therapy of 
tumors where current treatment regimens fail. 
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Supplemental Figure 4.2: Lentiviral transductions of FOXM1 
(A) ESC mRNA signature score and FOXM1 expression levels in 29 neuroblastoma cell lines. (B) IMR-
32 cells were transduced with shRNA targeting FOXM1, followed by quantitative RT-PCR assessment 
of FOXM1. Error bars represent the standard error of mean (technical duplicates). (C) Western Blot 






Supplemental Figure 4.3: FOXM1 also drives the ESC mRNA signature score in other cancer entities 
A) ESC mRNA signature score upon lentiviral inhibition of FOXM1 in glioma cells, (B-C) upon siRNA 
FOXM1 inhibition in breast cancer cells, (D) upon inhibition of FOXM1 with siomycin A in glioma stem 
cells, (E) upon inhibition of FOXM1 with siomycin A in prostate cancer cells and (F) in breast cancer 


























































































































































































































Supplemental Figure 4.4: ESC mRNA signature score is related to survival 
(A-B) Kaplan-Meier and log rank analysis on 200 neuroblastoma patients with a high or low ESC 
mRNA signature score. (C-D) Kaplan-Meier and log rank analysis within the subset of stage 4 
neuroblastoma without MYCN amplification. Kaplan-Meier and log rank analysis of 498 
neuroblastoma patients with high or low ESC mRNA signature score (independent validation), in the 
global cohort (E-F) and with the subset of stage 4 neuroblastoma without MYCN amplification (G-H). 
(I-J) ESC mRNA signature score in neuroblastoma patients with or without MYCN amplification in the 
global cohort and stage 4 neuroblastomas only.  
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Supplemental Figure 4.5: ESC mRNA signature scores in other cancer entities with or without 
MYCN amplification 
A) CCLE database analysis of the ESC mRNA signatures in MYCN non-amplified and MYCN amplified 
cancer cell lines. (B) ESC mRNA signature scores in medulloblastoma samples with and without MYCN 
amplification.  
 
Supplementary Table 4.1: Genelists from 4 published studies reporting of differential 
miRNA expression analysis of ESC versus more differentiated cells.  
 
Supplementary Table 4.2: list of coding genes ranked according to the degree of expression 
correlation with the ESC miRNA signature score in 200 neuroblastoma tumor samples.  
This list is available in a digital format only and can be sent upon request. 
 
Supplementary Table 4.3: results obtained by iRegulon. 
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Supplementary table 4.1: Genelists from 4 published studies reporting of differential 
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Supplementary Table 4.3: results obtained by iRegulon. 
 
  # Rank AUC NES Cluster code Transcription 
1 0.233221 9.52503 T1 E2F4 
2 0.209607 8.43827 T2 TFDP1 
3 0.169315 6.58396 T1 E2F4 
4 0.166763 6.46649 T1 E2F4 
5 0.156578 5.99775 T3 E2F7 
6 0.149856 5.68839 T4 SIN3A 
7 0.136635 5.07995 T4 SIN3A 
8 0.134474 4.98049 T5 MYBL2 
9 0.13371 4.94532 T6 FOXM1 
10 0.131124 4.8263 T1 E2F4 
11 0.128446 4.70306 T6 FOXM1 
12 0.127633 4.66564 T6 FOXM1 
13 0.120746 4.34869 T6 FOXM1 
14 0.110909 3.89598 T4 SIN3A 
15 0.108158 3.76937 T4 SIN3A 
16 0.10726 3.72801 T7 E2F1 
17 0.102885 3.52669 T4 SIN3A 
18 0.101739 3.47394 T4 SIN3A 
19 0.0987036 3.33424 T4 SIN3A 
20 0.0928438 3.06456 T6 FOXM1 
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Neuroblastoma is the most common extracranial pediatric solid tumor in children, 
accounting for approximately 7-10% of pediatric cancers. Despite intensive multimodal 
therapies, survival rates for patients with aggressive forms of neuroblastoma are still 
disappointingly low and therefore new treatment options are warranted. The forkhead box 
protein M1 (FOXM1) is a transcription factor mainly involved in cell cycle and the DNA 
damage repair pathway and has been described as an oncogene in many cancer, including 
neuroblastoma. Siomycin A and FDI6 are two compounds that target FOXM1 and were 
evaluated for their efficacy in neuroblastoma cells. Unfortunately no convincing results could 
be obtained, in fact, both drugs only introduced a modest effect on FOXM1 levels and either 
resulted in antagonistic effects in combination experiments with frequently applied 
chemotherapeutics (Siomycin A) or experienced fast drug resistance (FDI6). 
  






FOXM1 is a transcription factor and mainly acts as a regulator of the cell cycle and the DNA 
damage repair pathway. In normal tissues, FOXM1 is detectable in progenitors with 
extensive proliferating capacity, whereas its expression is depleted in differentiated or 
resting cells. Because of its role in cell proliferation and DNA damage, it is not surprising that 
FOXM1 has been described as an oncogene in many cancers including neuroblastoma1 
(Vanhauwaert et al. CCR, submitted). Interestingly, in a meta-analysis of expression 
signatures of over 18 000 human tumors, FOXM1 was identified as a major predictor of 
adverse patient outcome2. In neuroblastoma, an increasing body of data is pointing at a 
crucial role of FOXM1 in MYCN driven oncogenesis. First, multiple highly transcriptionally 
upregulated genes such as BRIP1, BIRC5 and TOP2A are direct targets of FOXM1. Second, 
several of these genes are located on chromosome regions commonly affected by copy 
number alterations, most notably chromosome 17q (Vanhauwaert et al. this thesis). Finally, 
a recent study describing the transcriptional alteration in mouse neural crest derived MYCN 
overexpressing neuroblastomas, a strong FOXM1 signature was also noted (Olsen et al., 
Oncogene, accepted). Given the recent identification of compounds proposed to target 
FOXM1, we decided to evaluate their effects on neuroblastoma cell growth and survival.  
 
Results and Discussion 
Inhibition of FOXM1 using thiazole antibiotics 
Siomycin A and in general all proteasome inhibitors have been described to target FOXM1, 
through stabilization of its negative regulator NRFM3. Indeed, upon administration of 
Siomycin A in the neuroblastoma cell line N206, a modest depletion of FOXM1 could be 
observed after 72h (Figure 5.1 A-B, Supplemental Figure 5.3A-B) together with evidence for 
reduced cell viability (Figure 5.1 C)4. Next, we tested Siomycin A in combination with 
chemotherapeutics frequently used in current neuroblastoma patient treatment protocols. 
Cisplatin has been described before to act synergistically with Siomycin A in 




neuroblastoma cells. Despite previous reports, no synergism could be observed in 
neuroblastoma cells lines N206, SK-N-SH, IMR-32 and SK-N-AS. In fact, surprisingly, in all cell 
lines strong antagonistic effects were seen (combination index > 1.5) (Figure 5.1D). Also 
other combinations with etoposide and doxorubicin resulted in strong antagonistic results 
(data not shown). Siomycin A is a thiazole antibiotic that targets FOXM1 indirectly via 
proteasome degradation and therewith also affecting the expression of several other 
proteins resulting in off target effects and possibly explaining our results.  
 
Figure 5.1: Effect of Siomycin A treatment on neuroblastoma cells. (A) Western blots of FOXM1 and 
the loading control β-actin upon Siomycin A treatment. (B) mRNA levels of FOXM1 after treatment 
with Siomycin A measured with RTqPCR. Error bars represent the standard error of mean (technical 
duplicates) (C) N206 neuroblastoma cells with and without Siomycin A treatment. Size of the white 
bar is 1000µM. (D) Dose response curves of Siomycin A, cisplatin and the combination 72h after 
treatment in N206 Combination index (CI) is 2.8. Error bars represent standard deviation of 2 
biological replicates.  




Inhibition of FOXM1 using FDI-6 
FDI-6 was identified through a high-throughput library screen and was described as the first 
presumed "on target" FOXM1 compound6. The authors showed that FDI-6 binds directly to 
the FOXM1 protein and displaces FOXM1 from it genomic targets in MCF-7 breast cancer 
cells. Indeed, when tested on IMR-32 neuroblastoma cells, knock down of FOXM1 
downstream targets was observed 6 hours. after addition of the drug (Figure 5.2A). 
However, 24h after adding FDI6, FOXM1 downstream targets were upregulated (Figure 
5.2B). We tested whether this was also the case in IMR-32 cells depleted for FOXM1 by 
shRNAs, but in this cell system the expected knock down was still observed (Figure 5.2C). To 
exclude effects due to fast degradation of the FDI-6 compound, we administered the drug 
every 12h to the cells, however this didn’t affect the outcome (data not shown). 
Interestingly, in the original report, the authors only showed knock down data no longer 
than 9h after administration, thus not allowing to compare our results for longer drug 
exposure.  
 
Figure 5.2: Administration of FDI6 in the neuroblastoma cell line IMR-32 (A-B) RT-qPCR results of 
FOXM1 downstream targets (A) 6 hours after administration of FDI6 (B) and after 24 hours. Error 
bars represent the standard error of mean (technical duplicates) (C). Relative mRNA expression of 
FOXM1 and downstream targets after FOXM1 knock down with shRNAs. Error bars represent the 





Because of its important roles in cell proliferation and DNA damage in cancer cells, FOXM1 
has been proposed as an important putative novel drug target. So far, several approaches 
have been described for molecular targeting of FOXM1, amongst others, Siomycin A and FDI-
6. We evaluated both Siomycin A and FDI-6 in neuroblastoma cells; however no convincing 
results could be obtained. In fact, both drugs only introduced a modest effect on FOXM1 
levels and either resulted in antagonistic effects in combination experiments with frequently 
applied chemotherapeutics (siomycin A) or experienced fast drug resistance (FDI-6). Recent 
discussion revealed that several unpublished data are in line with our observations and 
support the notion that neither Siomycin A nor FDI-6 are on target compounds to inactivate 
FOXM1 activity. More recently, a kinase inhibitor MELK-T1, identified through a drug screen 
by Johnson and Johnson, shown to target the FOXM1 upstream regulator MELK, has been 
shown to have significant on target effects and will soon be tested extensively in the host 
lab. While our results were disappointing, this novel drug may hold great promise while 
further efforts to screen for FOXM1 targeting drugs are warranted.  
  




Material and methods: 
 
Compound administration 
Neuroblastoma cell lines were grown as monolayer cultures at 37°C and 5% CO2 as in a 
humid atmosphere. The culture medium was RPMI 1640 (GIBCO, Life Technologies) 
containing 10% Fetal Calf Serum (FCS), 2mmol/l glutamine and the following antibiotics: 
Penicillin (1%), Kanamycin (1%) and Streptomycin (1%). Siomycin A (Sigma Aldrich) and FDI-6 
(STK166499; Merlin Consultancy) were dissolved in DMSO and stored as 2mM (Siomycin A) 
and 5mM (FDI-6) stock solutions at -20°C. Keeping the final concentration of DMSO constant, 
cells were treated with Siomycin A with concentration ranging from 0 to 0.8µM, with 
Cisplatin with concentration ranging from 0µM to 48µM and for FDI-6 with a concentration 
of 10µM, for the time periods indicated. CI for the drugs was calculated using calcusyn. 
 
Western blotting 
Protein extraction was done via RIPA buffer and protein concentration was measured using 
the Lowry protein assay. Protein extracts were separated with SDS-PAGE, blotted on a 
nitrocellulose membrane and probed with antibodies against FOXM1 (1/1000; 5436S cell 
signaling), and β-actin (1/10000, A2228, Sigma-Aldrich). Proteins were detected with HRP-
conjugated goat anti rabbit IgG antibody (1/15000, A27036, thermos fisher scientific) and 
developed with ChemiDoc-it imaging system (UVP). 
 
RT-qPCR 
RNA isolation was performed using the miRNeasy micro kit, according to the guidelines of 
the company (Qiagen, catalogue number 217084), including DNAse treatment on column 
(RNAse-free DNAse set, Qiagen, catalogue number 79254). cDNA synthesis was carried out 
using 500ng of RNA with the iScript cDNA synthesis kit (Bio-Rad, catalogue number 170-
8891). RT-qPCR primers for FOXM1 (AGACACCCATTAAGGAAACG,TTTGTACTGGGCTGAAATCC) 
and reference genes HPRT1(TGACACTGGCAAAACAATGCA ,GGTCCTTTTCACCAGCAAGCT), 




(TGGGAACAAGAGGGCATCTG, CCACCACTGCATCAAATTCATG) were designed using primerXL 
(www.primerXL.org). RT-qPCR reactions were performed in duplicate in a total volume of 
5µl, including 2µl of cDNA and 3µl of ssAdvanced SYBR Green qPCR mastermix (Bio-Rad). 
Cycling conditions were 95°C (15s) – 60°C (15s) – 72°C (60s) and 44 cycli. Data analysis was 
performed using the qBasePlus software (Biogazelle) 
FOXM1 silencing through shRNAs 
ShRNA knock down for FOXM1 was achieved using MISSION shRNA (Sigma) 
TRCN0000015544. Viral production was performed with 15 µg of plasmid in 3 million 
HEK293TN cells using the calcium phosphate trans-lentiviral packaging system, according to 
the protocol provided by the manufacturer (Life technologies). The viral particles were 
concentrated using the PEG-it virus precipitation protocol (System Biosciences) and 
afterwards transduced in the neuroblastoma cell line IMR-32.  
 
Cell growth assessment 
xCELLigence MP (Roche Diagnostics) was used to monitor cell proliferation. Background 
impedance was measured before seeding the cells using 40µl of RPMI 1640 containing 10% 
FCS and always subtracted as blank value. 1xE4 cells in 50µl of RPMI supplemented with 10% 
FCS were added. Cell proliferation was measured with a programmed signal detection every 
hour. Data acquisition and analysis was performed with the RTCA software (version 1.2, 
Roche Diagnostics).  
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Supplemental Figure 5.3: Validation of Siomycin A efficacy in neuroblastoma cell lines. (A) Western 
blots of FOXM1 and the loading control β-actin upon Siomycin A treatment in CLB-GA and SK-N-SH. 
(B) Relative mRNA expression of FOXM1 downstream targets after FOXM1 knock down with Siomycin 
A. Error bars represent the standard error of mean (technical duplicates) 
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The selection and validation of stably expressed reference genes is a critical issue for proper 
RT-qPCR data normalization. In zebrafish expression studies, many commonly used 
reference genes are not generally applicable given their variability in expression levels under 
a variety of experimental conditions. Inappropriate use of these reference genes may lead to 
false interpretation of expression data and unreliable conclusions. In this study, we 
evaluated a novel normalization method in zebrafish using expressed repetitive elements 
(ERE) as reference targets, instead of specific protein coding mRNA targets. We assessed and 
compared the expression stability of a number of EREs to that of commonly used zebrafish 
reference genes in a diverse set of experimental conditions including a developmental time 
series, a set of different organs from adult fish and different treatments of zebrafish 
embryos including morpholino injections and administration of chemicals. Using geNorm 
and rank aggregation analysis we demonstrated that EREs have a higher overall expression 
stability compared to the commonly used reference genes. Moreover, we propose a limited 
set of ERE reference targets (hatn10, dna15ta1 and loopern4), that show stable expression 
throughout the wide range of experiments in this study, as strong candidates for inclusion as 
reference targets for qPCR normalization in future zebrafish expression studies. Our applied 
strategy to find and evaluate candidate expressed repeat elements for RT-qPCR data 
normalization has high potential to be used also for other species. 
 
  





Reverse transcription quantitative PCR (RT-qPCR) is currently regarded as the gold standard 
for efficient measurement of mRNA gene expression, especially because of its high 
sensitivity, specificity, accuracy and precision, but also because of its practical simplicity and 
processing speed. However, variable yields of RNA extraction and reverse transcription and 
also variable amplification efficiencies can affect RT-qPCR results1,2. To correct for technically 
induced variation and thus measure true biological variation in samples, it is important to 
apply a good normalization strategy. The use of multiple reference genes as internal controls 
is the most frequently applied and recommended procedure for normalizing RT-qPCR data3-
7. In this respect, specific attention should be given to the correct selection and validation of 
reference genes for normalization, as stated in the MIQE (Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments) guidelines1. The selected reference 
genes should be stably expressed in the studied samples and should thus show a strong 
correlation with the total amount of mRNA present in the samples. Importantly, many 
commonly used reference genes are not generally applicable as their expression stability 
greatly varies under different experimental conditions8-11. Therefore, it is essential to 
determine the optimal number and choice of reference genes for the specific experimental 
conditions in every study. A number of studies have measured and compared the expression 
stability of a set of commonly used reference genes in samples derived from different 
species, organs, cells, developmental stages, and treatments, using one of the available tools 
that automatically calculate expression stability values (geNorm, BestKeeper, Normfinder)8-
11. These studies propose the set of most stably scored reference genes as being the most 
suitable for normalizing gene expression data. However, the determination of stable 
reference genes only occurs in a comparative fashion and the detection of the ‘most stably’ 
expressed genes does not necessarily mean they are stably expressed in other conditions. 
Especially developmental time series and the comparison of different tissues are challenging 
experimental conditions to normalize8,11,12. Therefore, the ideal situation of using only one 
set of reference genes to cover all experimental conditions in a specific species has not been 
feasible up to now.  
 




human samples13-15. This novel normalization method uses expressed repetitive elements 
(ERE) as reference targets, instead of protein coding mRNAs. Here, we illustrate the 
usefulness of this approach for zebrafish expression data. The zebrafish (Danio rerio), a small 
teleost fish, is a popular vertebrate model organism for a number of reasons, including the 
low maintenance cost, short reproductive cycle, external fertilization and development, 
production of large numbers of synchronous and rapidly developing embryos per mating and 
the optical transparency of zebrafish embryos. Moreover, the availability of a wide range of 
molecular techniques, such as overexpression/knockdown approaches, transgenesis, large-
scale genome mutagenesis and lately also highly efficient targeted mutagenesis (using ZFN, 
TALEN and CRISPR-Cas technology) make zebrafish an excellent tool for high-throughput 
disease modeling. Finally, molecular genetic mechanisms and cellular physiology are highly 
similar between zebrafish and other vertebrates, underscoring the relevance of zebrafish for 
the modeling of human diseases.  
 
We assessed and compared the expression stability of a number of EREs in the zebrafish 
transcriptome to a set of commonly used zebrafish reference genes in a developmental time 
series, in different organs from adult fish and under different treatments of zebrafish 
embryos including morpholino injections and administration of chemicals. Here we 
demonstrate that EREs outperform classically used reference genes and put forward a 
selection of EREs as strong candidates for inclusion as reference targets for qPCR 
normalization in a diverse set of zebrafish experiments. The procedure followed here for 
identification of zebrafish reference EREs can also easily be applied for other species. 
 
  




Materials and Methods 
 
Zebrafish maintenance and imaging  
Wild-type AB zebrafish, obtained from the zebrafish international resource center (ZIRC) 
were maintained in 3.5 liter tanks in Zebtec semi-closed recirculation housing systems 
(Tecniplast, Italy) at a constant temperature of 28 °C and a 14 h light 10 h dark photoperiod. 
Fish were fed 4 times a day with both dry feed (SDS, UK) and brine shrimps (Ocean Nutrition, 
Belgium). After in vitro fertilization, dead embryos were removed at 8 hpf (hours post 
fertilization) and at 24 hpf surviving embryos were dechorionated with pronase (Sigma, St. 
Louis, MO, USA). At 48 hpf or 72 hpf, embryos were anesthetized with 0.016% tricaine 
methanesulfonate (tricaine) and mounted in 2 % methylcellulose and imaged using a Leica 
M165FC stereomicroscope. Approval for this study was provided by the local committee on 
the Ethics of Animal Experiments (Ghent University Hospital, Ghent, Belgium; Permit 
Number: ECD 11/37). All efforts were made to minimize pain and discomfort.  
 
Morpholino injections 
Morpholinos (MOs) are small antisense oligonucleotides that bind the mRNA of interest, 
resulting in a down regulation of the gene expression. In this screen, MOs targeting chordin 
and slc2a10 were injected. A scrambled MO was also included as a negative control. Chordin 
encodes for a secreted protein that dorsalizes early vertebrate embryonic tissues and is 
often used as a positive control in MO experiments16. Chordin-MO injected embryos display 
abnormal u-shaped somites, an expanded blood island and an abnormal tail fin with multiple 
folds. Slc2a10 encodes for GLUT10, a member of the glucose transporter family. Recessive 
mutations in this gene are causing the arterial tortuosity syndrome (ATS)17. In zebrafish 
embryos, knockdown of slc2a10 using MO injection causes a wavy notochord and 
cardiovascular abnormalities with a reduced heart rate and blood flow, which was coupled 
with an incomplete and irregular vascular patterning18. Morpholino oligonucleotides were 
obtained from Gene Tools, LLC (Philomath, OR, USA). The MO against slc2a10 (5′-
CAAATAAAGTCCACTTACTTGGTCC-3′) is directed against the exon 2–intron 2 donor splice site 




ATCCACAGCAGCCCCTCCATCATCC–3´)16. A control MO (5’-CCTCTTACCTCAGTTACAATTTATA-
3’) was used as a negative control in each experiment. MOs were microinjected in 1.5 nl 
volume into 1- to 2-cell stage embryos at 7.5 ng for slc2a10, 2 ng for chordin, and 5 ng for 
the control MO. All MOs were dissolved in 0.1 % phenol red and 1x Danieu’s buffer [58 mM 
NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5.0 mM HEPES (pH 7.6)]. 
Microinjection procedures were performed using a Leica M80 stereomicroscope. At 48 hpf, 
embryos were dechorionated, euthanized with 0.4% tricaine, and triplicate pools of 20 
embryos were collected in RNAlater (Sigma-Aldrich, St. louis, USA).  
 
Compound treatments 
Two different chemical treatments were performed: embryos were treated with 40 µM of 
TGFβ type 1 receptor kinase inhibitor (TGFBRI, LY-364947, #L6293, Sigma, St. Louis, USA), or 
194 µM of warfarin (Coumadin, #45706 Sigma, St. Louis, USA). TGFBRI specifically targets the 
TGFBR1 kinase function resulting in the inhibition of phosphorylation of SMAD2 and SMAD3 
and down regulation of TGFβ signaling. Treatment of early embryos with this inhibitor 
results in cardiovascular abnormalities including condensation of the caudal vein plexus, low 
heart rate and reduced blood flow18. Warfarin, is an oral anticoagulant drug used in 
treatment of thromboembolic diseases19. Warfarin acts as a vitamin K antagonist, and 
vitamin K is needed as a cofactor for the carboxylation of glutamate residues of several 
clotting factors. Administration of warfarin to early embryos produces teratogenic effects 
including developmental delay, growth retardation, eye defects, scoliosis and ear defects20. 
TGFBRI and warfarin were prepared as a 20 mM and 80 mM stock solution respectively in 
DMSO. Working solutions, 0 and 40 µM for TGFBRI and 0 and 194 µM for warfarin, were 
made in E3 chemical screening medium21 and as previously described18,20, embryos were 
incubated in the compounds starting at 8 hpf (TGFBRI) and 2.5 hpf (warfarin), dechorionated 
at 24 hpf, euthanized with 0.4% tricaine, and collected in triplicate pools of 20 embryos in 
RNAlater at 48 hpf (TGFBRI) or 72 hpf (warfarin). 
 
Developmental time series embryos/larvae and dissection of organs from adult zebrafish 
At several time points (0 hpf, 8 hpf, 24 hpf, 48 hpf, 72 hpf, 96 hpf, 6 dpf, 8 dpf, 10 dpf and 12 
dpf), triplicate pools of 20 embryos/larvae were collected, euthanized with 0.4% tricaine, 
and stored in RNAlater. Dissection of the eye, brain, skin, testis, liver, intestines and ovaria 




from two adult fish was performed as previously described 22. After dissection, the organs 
were immediately snap frozen using liquid nitrogen. Subsequently they were sectioned (50 




RT-qPCR reactions were performed and reported according to MIQE guidelines1. If needed, 
RNAlater was first removed from samples with a glass Pasteur pipette and RNA isolation was 
performed using the miRNeasy mini kit (Qiagen) in combination with on-column DNase I 
treatment using the RNase-Free DNase set (Qiagen) according to the manufacturer’s 
guidelines. RNA quality index (all RQI>8) was measured for all the samples using an Experion 
automated electrophoresis system (software version 3.2, Bio-Rad). As the RNA 
concentration of the adult tissue samples was low, whole transcriptome amplification for 
these samples was executed as previously described (NuGEN) 23. cDNA was synthesized from 
1µg RNA in a 20 µl reaction with the iScript kit (Bio-Rad) using a blend of oligodT and random 
hexamer primers. qPCR reactions were performed in a total volume of 5 µl, comprising 2.5 µl 
SsoAdvanced SYBR Green Supermix (Bio-Rad), 5 ng (total RNA equivalents) cDNA and 250 
nM (final concentration) of each primer on a LightCycler 480 qPCR instrument (Roche) in 
384-well white plates (Bio-Rad). Thermocycling conditions were as follows: 95°C for 2 min, 
followed by 44 cycles of 95°C for 5 s, 60°C for 30s, 72°C for 1s and finally a melting curve 
analysis was performed at 95°C for 5s followed by 60°C for 1 min, gradual heating to 95°C at 
a ramp-rate of 0.11°C/s followed by cooling to 37°C for 3 min. Primers for bactin2, elfa, 
cyp19a1b, hprt1, rps18, tbp, rpl13a, tuba1 and b2m were designed using primerXL software 
(http://primerxl.org/). Primer sequences for gapdh were taken from literature11. Primers for 
the newly identified expressed repeats were designed with primer3 software 
(http://primer3.ut.ee/) using default settings24. Primer efficiencies were tested using a 
standard dilution series: RNA extracted from different developmental stages of zebrafish 
embryos (8, 24, 30, 48, 72, 96 hpf) was pooled and converted to cDNA to make a standard 
dilution series ranging from 16 ng to 0.0625 ng (Supplemental Figure 6.1A). Primer specificity 
was evaluated using melt-curve analysis (Supplemental Figure 6.1B). Primer efficiencies were 
also determined using LinRegPCR software25. For this, the raw, non-baseline-corrected qPCR 




Table 6.1. Reference target primer design and calculation of amplification efficiencies.  
 
software. A complete overview of all primer sequences and concomitant PCR efficiencies 
used in this study can be found in Table 6.1 and Supplemental Table 6.1.  
 
Statistics and data analysis 
The geNorm module in qbase+ version 2.5 (Biogazelle, http://www.qbaseplus.com) was used 
to compute expression stability values for all reference targets. As input for geNorm analysis, 
either Cq values exported directly from the LightCycler 480 software or efficiency-corrected 
Cq values from LinRegPCR that were calculated based on the raw, non-baseline-corrected 
LightCycler 480 qPCR data, were used. GeNorm calculates the gene expression stability 
measure M (M-value) for a reference gene as the average pairwise variation V for that gene 
with all other tested reference genes. Stepwise exclusion of the gene with the highest M 
value allows ranking of the tested genes according to their expression stability. GeNorm was 
also used to dertermine the optimal number of reference targets for every experiment. The 
geNorm algorithm determines the pairwise variation Vn/n+1, between two sequential 
normalization factors containing an increasing number of genes. A large variation means 
that the added gene has a significant effect and should preferably be included for calculation 
of a reliable normalization factor. Vandesompele et al. (2002) 7 used 0.15 as a cut-off value, 
below which the inclusion of an additional reference gene is not required. 




Rank aggregation analysis was performed in the R statistical programming environment 
(version 3.0.2) using the Rankaggreg package (version 0.4-3) 26 to determine the best ranked 







Identification of candidate expressed repeat element (ERE) reference targets in the zebrafish 
genome  
Candidate ERE reference targets in the zebrafish genome were extracted from Repbase 
(http://www.girinst.org/repbase), a database of repetitive DNA elements from different 
organisms27 (Figure 6.1). From an initial set of 1172 repetitive elements present in the 
zebrafish genome, only those having more than 100 copies in the genome were retained, 
leaving us with 74. To identify the number of expressed loci per repetitive element, a blastn 
search against all RefSeq and non-RefSeq annotated transcripts known for zebrafish was 
carried out using the consensus repeat sequence listed in Repbase. Only repeats with a total 
number of combined RefSeq and non-RefSeq blast hits above 30 and with a mean 
conservation rate higher than 85% (indicated by Repbase) were retained, resulting in 10 
candidate EREs for further analysis (tc1n1, dna11ta1, tdr7, dna15ta1, cr1-1, hatn8, hatn10, 
hatn4, loopern4, sine3). The thresholds of 30 and 85% were empirically determined in order 
to have a top-ranked list containing a manageable number of candidate expressed repeat 
elements. Next, qPCR assays were designed to target the most conserved region of the 
selected EREs (Table 6.1 and Supplemental Figure 6.2). Blasting of the primer sequences 
against the zebrafish RefSeq RNA database using primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) revealed that the amplified ERE 
fragments are exclusively located in untranslated gene regions, predominantly 3’UTR. 
To investigate the potential of EREs for qPCR normalization, we aimed to compare the 
expression stability of the 10 candidate EREs with that of 10 commonly used reference genes 
in zebrafish studies. The reference genes bactin2, elfa, cyp19a1b, hprt1, rps18, tbp, rpl13a, 
tuba1, b2m and gapdh were selected because of their frequent use in zebrafish expression 
studies. The amplification efficiency of all primer pairs was assessed using a zebrafish cDNA 
dilution series as a template, wherein efficiencies between 90 and 110% were attained 
indicating sufficient reaction efficiencies (Table 6.1 and Supplemental Table 6.1). 

















Determination of reference target expression stabilities under a wide range of conditions 
For the 20 candidate reference targets (10 EREs and 10 commonly used reference genes) 
mRNA expression levels were measured in a wide range of experimental settings including a 
zebrafish developmental time series (0 hpf up to 12 dpf), a set of different organs dissected 
from adult fish and a set of different treatments of zebrafish embryos including the 
administration of chemicals and injection of morpholinos (MO) (see Methods). The average 
expression stability for each of the reference targets in the 4 different types of experiments 
was calculated using the geNorm algorithm. Reference genes are ranked according to their 
expression stability value (referred to as the M-value) 7; in addition, the optimal number of 
genes for normalization is determined for each experiment. Reference targets with M-values 
below 0.5 and 0.2 are considered having a ‘high’ and ‘very high’ expression stability, 
respectively 12. In the experiments where embryos were treated with compounds or injected 





with MOs almost all reference targets had a ‘high’ expression stability and a considerable 
number of reference targets showed a ‘very high’ expression stability (Figure 6.2A-D). 
 
 
Figure 6.2. Average expression stability of common reference genes and expressed repeat 
elements. 
Ranking of reference targets depending on their M-values calculated by geNorm. Reference targets 
with M-values below 0.5 and 0.2 are considered having a ‘high’ and ‘very high’ expression stability, 
respectively. EREs are indicated in black, commonly used reference mRNAs in grey.   
 
  




In general, the EREs showed higher expression stabilities (lower M-values) compared to the 
reference genes, although differences in M-values are small. In the developmental time 
series and the comparison of the different zebrafish organs, the M-value distribution was 
more dispersed with relatively low expression stability (M>0.5) for the reference genes and 
‘high’ to ‘very high’ expression stability for a considerable number of EREs (Figure 6.2E,F). In 
the time series, the ERE hatn10, was identified as the best reference target, with an M-value 
around 0.3, while the best performing mRNA reference gene was rps18 with an M-value 
around 0.6 (Figure 6.2E). Of note, gapdh, a frequently used reference target in zebrafish, had 
an M-value of 1.5, which is considered as highly unstable. In the different zebrafish organs 
(Figure 6.2F) the best reference target is the ERE hatn10, with an M-value of 0.3, while the 
best classically used reference gene, bactin2, had an M-value of only 0.8. Similar results were 
obtained by performing a geNorm analysis for the 6 different experiments, using efficiency-
corrected Cq values that were determined by linear regression analysis of qPCR fluorescence 
data using LinRegPCR software (Supplemental Figure 6.3)25. To determine the optimal 
number of reference targets to be used in the different experiments, the Vn/n+1 value was 
calculated using geNorm (see Materials and Methods). This analysis indicated that for each 
experimental condition the inclusion of the best two reference targets is sufficient for 
adequate normalization as indicated by V2/3 values below 0.15 (Supplemental Figure 6.4, 
0.15 threshold according to Vandesompele et al. (2002)7). In 5 out of 6 conditions the best 
two reference targets were EREs.  
Finally, we aimed to identify the most stably expressed reference targets throughout the 
different experiments performed. A rank aggregation method based on voting theory (Borda 
count) was used to combine the 6 ranked lists of reference targets, generated for the 6 
different experiments. This method tries to find an ordered list of reference assays as close 
as possible to all individual ordered lists by calculating the weighted Spearman’s footrule 
distance, and using a cross-entropy Monte Carlo algorithm or genetic algorithm. The analysis 
of the 6 ordered reference target lists, clearly demonstrated that most of the EREs showed a 
higher overall expression stability compared to most of the commonly used reference genes, 
as evidenced by lower ranks and by the lower median M-value (Student’s t-test; p<0.001) 
and smaller spread of the M-value (Student’s t-test; p<0.001) (Figure 6.3A,B), with the 




0.5 and this ERE was found to be the most stably expressed reference target in 4 out of 6 
experiments, indicating that hatn10 is an interesting candidate for inclusion as a reference 
target in a broad range of experiments.  
 
Assessment of the validity of ERE reference targets versus common reference genes to 
normalize genes of interest 
To test the accuracy of qPCR results after normalization with either frequently used 
reference genes (gapdh, bactin2 and elfa) or ERE reference targets (hatn10, dna15ta1 and 
loopern4), the expression of known differentially expressed genes was measured in a diverse 
set of experimental conditions (developmental time series, different organs, morpholino and 
compound treatments).  
According to earlier reports, zorba transcripts are only present in zebrafish embryos until the 
mid-blastula transition (MBT) at about 3.5 hpf, after which zygotic transcription is 
initiated28,29. This means that zorba transcripts are strictly maternally derived with almost no 
zygotic transcription. This was validated by microarray data reported by Yang et al. (2013)30, 
where transcriptomes were compared between different developmental stages in zebrafish 
embryos. We looked at zorba expression in a developmental time series using RT-qPCR and 
normalized the data either with frequently used reference genes or with ERE reference 
targets. When using the ERE’s as reference targets, a more than 20 fold expression 
difference was noted between the 0 hpf (maternal) and 8 hpf (zygotic) time points, 
confirming that zorba transcripts are almost exclusively maternally derived (Figure 6.4A). 
When applying the classic reference genes for normalization, only a threefold expression 
difference was observed, falsely indicating a relatively small expression difference for zorba 
between maternal and zygotic transcription stages.  
During early embryogenesis, the pax6a gene is expressed in specific parts of the developing 
brain, although from larval stages on, expression gets more restricted to the eye31. 
Predominant eye expression of pax6a is further evidenced by microarray expression analysis 
(own data, not shown) revealing a 25% higher pax6a expression in the adult zebrafish eye 
compared to the brain. We looked at pax6a RT-qPCR expression levels in different organs 
from adult zebrafish. When expression levels were normalized to the ERE reference targets, 
the higher expression of pax6a in the eye versus the brain could be confirmed (Figure 6.4B). 




In contrast, normalization to the common reference genes resulted in an unexpectedly 
higher expression of pax6a in the brain compared to the eye.  
In zebrafish embryos, knockdown of slc2a10 using MO injection affects the expression of a 
number of genes involved in cardiovascular development, as evidenced by microarray 
expression analysis18. One of these prototypical affected genes is acta2, showing a small 
upregulation upon slc2a10 knockdown. We conducted RT-qPCR expression analysis for acta2 
and revealed that both common reference gene and ERE normalization resulted in a similar 
slight upregulation of the acta2 gene after slc2a10 MO injection (Figure 6.4C). The acta2 
gene is also known to be upregulated upon treatment with TGFBRI compound to a greater 
extent than after slc2a10 MO injections18. We confirmed a threefold overexpression of acta2 
upon administration of TGFBRI compound, both after common reference gene and ERE 






Figure 6.3. Rank aggregation analysis. 
A: Box plot representation of dispersion of the M-value. Boxes depict first and third quartile and the median is indicated with a line in the middle of the box, 
outliers are drawn as circles. Reference targets are ranked according to rank aggregation outcome (most stable reference targets on the left). B:Rank 
aggregation analysis ordering the reference genes, based on their rank position according to each stability measurement (grey lines), from the most stable 
(left) to the least stable (right). Mean rank position of each gene is shown in black, as well the model computed by the Monte Carlo algorithm (red line). All 
EREs, except for sine3, are ranked better than the commonly used reference genes. .







Figure 6.4. Fold change expression of selected genes of interest after normalization with common 
reference genes (ref. genes) and with ERE reference targets (ERE).  
A: Fold change expression of zorba between 0 hpf and 8 hpf. B: Fold change expression of pax6a 
between adult zebrafish eye and brain tissues. C: Fold change expression of acta2 between slc2a10 
MO and scrambled MO injections. D: Fold change expression of acta2 between TGFBRI compound and 







Several reports indicate that, even within a species, no single gene can be regarded as an 
ideal reference gene for the normalization of qPCR data across diverse sample types and 
experimental situations8,10,32. This is due to variations in expression levels of these genes 
across different experimental conditions, developmental stages or across different tissues or 
cells. In this study, we specifically aimed to identify a set of reference targets that are stably 
expressed over a diverse set of samples obtained from the zebrafish, a model organism 
which is becoming increasingly popular in disease modeling, developmental studies and 
toxicology. Our strategy was based on the identification of specific types of repetitive 
elements that have spread throughout the zebrafish genome during evolution and that are 
also present in genomic sequences that are transcribed to RNA. With a single pair of RT-
qPCR primers, one specific expressed repetitive element (ERE) can be amplified, thereby 
simultaneously detecting numerous different transcripts in which the specific ERE is present. 
The underlying assumption is that by measuring many transcripts at the same time, 
differential expression of a few of them will not drastically alter the total level of ERE 
expression. Therefore, expression of this set of repeats is expected to be highly stable 
throughout different experimental situations, as it serves as an estimation of the general 
mRNA fraction abundance. The use of expressed repeat elements was first presented by 
Vandesompele et al. (2nd International qPCR Symposium, Freising-Weihenstephan, 
Germany, September 6, 2005) and subsequently confirmed by Marullo et al. (2010)13 where 
primate specific Alu repeats were used for normalization of biomarkers in human blood. 
Recently, it has been reported that expressed Alu repeats can be successfully used as a 
normalization factor in RT-qPCR experiments where human cancer cells were subjected to 
various perturbations14 or in human embryonic stem cell differentiation experiments15.  
In this study, 10 different zebrafish EREs were selected as candidate normalization targets 
based on a minimal number of expressed copies and conservation score. Subsequently, 
expression stability of these EREs and 10 commonly used reference mRNAs for zebrafish 
studies were compared. The standard reference genes are involved in different cellular 
processes and structures such as metabolism (hprt1, gapdh), transcription (tbp), translation 
(elfa), cytoskeletal structure (bactin2, tuba1), major histocompatibility complex (b2m) and 
steroid biosynthesis (cyp19a1b), thus avoiding co-regulation upon different 




treatments11,32,33. We did not include the frequently used rRNA transcripts (e.g. 18S and 28S 
rRNA) into this study. Indeed, while rRNA represents more than 90% of total RNA, it has 
been shown that the rRNA to mRNA ratio can vary depending on the experimental 
condition34-36. Moreover, the high abundance of rRNA compared to mRNA may hamper the 
correction of the baseline fluorescence in qPCR data analysis7,37. Finally, rRNA is transcribed 
by a different endogenous RNA polymerase, is not polyadenylated, and has a different 
function compared to mRNA, making ribosomal RNA a non-representative form of RNA for 
normalization of mRNA. Therefore, the use of rRNA as a normalization factor in qPCR 
experiments is not recommended and could lead to false interpretation of the data.  
Expression stabilities were tested in a diverse sample set, covering different experimental 
setups in zebrafish research, including morpholino and compound treated samples and 
samples from different developmental stages and from different adult tissues. Especially for 
the latter two sample types, good quality normalization factors are difficult to find11, most 
likely because of dramatic changes in expression profiles during zebrafish development and 
major differences in expression between different matured organs30,38. Indeed, expression 
analysis in different developmental stages and tissues from zebrafish, revealed a poor 
expression stability of all commonly used reference mRNAs with M-values higher than 0.5, 
implying that these genes are not suitable for reliable normalization of expression data in 
these experimental conditions. Strikingly, the expression of one of the most frequently used 
reference genes, gapdh, is the least stable of all reference targets tested in this study. In 
keeping with this observation, previous studies in vertebrate tissues and cell lines have 
already reported on the poor performance of gapdh as an internal reference gene and on its 
expression variability39-43. Consequently, we would strongly discourage further use of gapdh 
as reference gene for normalization in zebrafish experiments. Remarkably, most of the 
zebrafish EREs performed very well, with in many cases M-values below 0.5, signifying a high 
expression stability, thus clearly marking EREs as the reference target of choice in these 
experimental conditions. The robustness of ERE normalization for expression analysis in 
different developmental stages and tissues from zebrafish was further evidenced by the 
validation of known differential expression levels for respectively the zorba and pax6a 
genes. Normalization with common reference genes resulted in completely different 
expression patterns, leading to false interpretation of the data. The performance of EREs in 




treatments or morpholino injections. While almost all reference targets scored relatively 
well, again expression stability of the EREs was generally better than for the common 
reference genes. The relatively good performance of all reference targets, regardless of their 
nature, in compound and morpholino experiments reflects the more subtle impact of these 
treatments on the general expression profile in zebrafish embryos. Indeed, validation of 
known differential expression levels for the acta2 gene in these conditions revealed no 
major difference between both normalization strategies. 
To identify the most stably expressed reference targets throughout all different experiments 
performed, we conducted a rank aggregation analysis. This analysis indicates that the 
expression stability of the EREs was better than for the common reference genes. ERE 
hatn10, dna15ta1 and loopern4 represent the most stable reference targets with M-values ≤ 
0.5 in all 6 experiments. We recommend including at least these 3 genes in zebrafish gene 
expression studies for evaluation of their suitability as normalization targets.  
The MIQE guidelines from 2009 emphasize the need for accurate normalization of RT-qPCR 
data in order to obtain reliable expression data. However, a recent paper in Nature Methods 
that surveyed 1700 publications with qPCR-based data from 2009 to 2013 reported the poor 
application of these guidelines including inadequate normalization procedures with 
widespread use of single, unvalidated reference genes44. It has long been recognized that 
this can lead to unreliable results, in particular for measuring subtle differences in expression 
levels. Our study fully complies with the MIQE guidelines and tackles the issue of proper 
normalization in zebrafish expression studies, by providing for the first time a set of robust 
candidate reference targets to normalize RT-qPCR data in a wide range of zebrafish 
experiments. EREs have the potential to dramatically facilitate and improve gene expression 
studies in zebrafish. In addition, the bio-informatics strategy outlined for identification and 
validation of such EREs in this study can be applied to other organisms. As such, we expect 
similar ERE qPCR assays to be developed and used in other model organisms for 
normalization purposes. 
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Supplemental Figure 6.1. Representative example of an ERE standard dilution and melting curve.  
A: Standard dilution curve, used to determine the primer amplification efficiency of the dna15ta1 
primer set. In this example Cq values obtained for the dna15ta1 primer set are plotted against the 
cDNA quantity (ng) (exported from qbase+ software). For each quantity two technical replicates are 
included. B: Melting curve analysis for the dna15ta1 primer set (exported from LightCycler 480 
software). On top, the sample fluorescence is plotted against temperature. Below, the first negative 
derivative of the sample fluorescence is plotted against temperature, displaying the melting 
temperature as a peak. In this example, there is a single sharp peak from an amplicon having a Tm of 
76 °C, indicating the specificity of the dna15ta1 primer set. 





Supplemental Figure 6.2. Schematic representation of ERE primer design (hypothetical example). 
The full-length repeat element (dark grey line, top) and a number of aligned repeat element 
containing fragments obtained from a combined RefSeq/non-RefSeq blastn search are depicted. In a 
first step we determine the part of the ERE sequence that is most frequently expressed. To delineate 
this area, all RefSeq and non-RefSeq blast results are aligned with the consensus repeat sequence 
and sequences that are commonly present in most of the fragments are used as a template for 






Supplemental Figure 6.3. Average expression stability of common reference genes and expressed 
repeat elements (based on LinRegPCR corrected Cq values). 
  





Supplemental Figure 6.4. GeNorm calculated pairwise variation Vn/n+1 values for the different 
experimental conditions.  
The optimal number of reference targets (n) is reached, when the inclusion of the next reference 
target (n+1) reduces the Vn/n+1 value below 0.15. For every experiment the V2/3 value is lower than 
0.15, indicating that the inclusion of only two reference targets, the ones with the lowest M-value, is 





Supplemental Table 6.1. Target specific amplification efficiency parameters. 
Reference 
target 










cr1-1 2.012 0.018 0.999 -3.293 101.22 1.85 
dna11ta1 2.076 0.04 0.994 -3.153 107.57 1.89 
dna15ta1 2.012 0.027 0.997 -3.295 101.14 1.94 
hatn10 2.043 0.013 1 -3.224 104.25 1.88 
hatn4 2.05 0.02 0.999 -3.208 104.98 1.87 
hatn8 2.025 0.027 0.997 -3.265 102.43 1.84 
loopern4 2.095 0.035 0.996 -3.114 109.47 1.87 
sine3 2.014 0.036 0.996 -3.288 101.44 1.86 
tc1n1 2.034 0.049 0.993 -3.242 103.45 1.88 
tdr7 2.022 0.036 0.996 -3.271 102.17 1.87 
b2m 1.946 0.057 0.992 -3.459 94.6 1.86 
bactin2 1.993 0.054 0.991 -3.340 99.3 1.86 
cyp19a1b 2.015 0.045 0.994 -3.288 101.5 1.84 
elfa 2.060 0.049 0.993 -3.187 106.0 1.88 
hprt1 1.957 0.042 0.994 -3.430 95.7 1.86 
rpl13a 1.912 0.040 0.994 -3.553 91.2 1.87 
rps18 1.987 0.042 0.994 -3.352 98.7 1.86 
tbp 1.954 0.055 0.990 -3.438 95.4 1.85 
tuba1 2.077 0.024 0.998 -3.150 107.7 1.89 




























They stumble that run fast 









Discussion and future perspectives 
 
NB is an embryonal tumor of the autonomic nervous system, emerging from neural crest 
derived precursor cells committed to the sympathetic neuronal lineage1. As a typical 
embryonal tumor, NB occurs mainly in very young children with the median age at diagnosis 
of 17 months2 and presents with low mutational burden. The ALK gene is the only major 
mutational target occurring in 8 to 10 percent of NB patients at diagnosis3,4. In contrast to 
the low mutation rates, recurrent DNA copy number alterations (CNAs) including MYCN and 
ALK amplifications and recurrent large and focal DNA partial gains and losses as well as 
whole chromosome imbalances are observed with a very high frequency5. Hence, NB has 
been coined a DNA copy number disease. One of the most prominent CNAs is gain of a large 
segment of the long arm of chromosome 17, with breakpoints being located within 
chromosome band 17q23 or distal thereof. Partial gains occur both in high risk NBs with and 
without MYCN amplification and are associated with poor patient outcome6. While 
mutations are rare and thus offering limited options for precision oncology, a better 
understanding of the molecular perturbations installed through these large CNAs can offer 
novel therapeutic targets and options for design of novel therapies. The search for these 
genes however is difficult: while it can be logically assumed that genes on 17q contribute to 
the tumor phenotype through dosage effects as has been described recently in 
ependymoma7, thus far, the size of the commonly gained region, estimated to be around 25 
Mb, has precluded the identification of these culprit genes.  
 
BRIP1 as a new cooperative oncogene in NB oncogenesis 
 
Through previous bio-informatic analysis using the CONEXIC algorithm, BRIP1 was selected 
as a strong 17q candidate cooperative driver oncogene (Fieuw A., thesis id 4390537). While 
the latter study was conducted on a relative small number of high stage tumors (with and 
without MYCN amplification), a further integrated and cross species genomics bio-informatic 
analysis described in this thesis confirmed BRIP1 (located on chromosome 17q23) as top 




support for this hypothesis as described in paper 1. Our data convincingly show that BRIP1 
acts through a gain of function mechanism, with tumor cells relying on high levels of BRIP1 
for survival and in vivo modeling in zebrafish demonstrating that elevated BRIP1 levels 
accelerate MYCN driven tumor formation thus in keeping with a cooperative oncogene 
function.  
The attribution of an oncogenic gain of function to BRIP1 in NB may be, at first glance, 
confusing given the well-established role of BRIP1 as tumor suppressor gene and its known 
role as Fanconi anemia gene. Indeed, BRIP1 is known to interact with BRCA1 and plays a 
crucial role in several DNA repair processes. This places BRIP1 in a growing list of genes that 
now have been recognized to act both as oncogenes and tumor suppressors depending on a 
given cellular or temporal context with best examples being NOTCH1 and EZH28,9. 
Interestingly, in familial breast cancer, in addition to inactivating BRIP1 mutations also a rare 
M299I variant was detected shown to result in a more robust repair of DNA interstrand 
crosslinks than wild type BRIP110, thus also pinpointing to an oncogenic role. In further 
support, BRIP1 expression levels are often elevated in breast cancer and infer a poor 
prognosis. While intriguing, further in depth mechanistic and functional studies, as done in 
this thesis for NB, are needed to better understand the possible opposing oncogenic 
functions of BRIP1 in breast cancer.  
BRIP1 protects NB cells from replicative stress  
As pointed out in detail in the introduction, replicative stress is the process characterized by 
the slowing or stalling of the replication fork11. Several causes for replicative stress have 
been described including shortage of nucleotides and replication factors, G-quadruplex 
structures, covalent protein-DNA adducts, R-loops, heterochromatin and DNA damage. Also, 
several oncogenes, including MYC and RAS,12 have been shown to cause replicative stress. 
Interestingly, while MYC is typically known as transcription factor controlling a broad range 
of genes driving cell cycle (amongst others)13,14, it has also been shown to directly interfere 
with control of initiation of replication through binding to origins of replication15. As such, 
MYC will boost overall replication speed which may render developing cancer cells 
particularly vulnerable to the above describes triggers for replicative stress. Of further 
importance in understanding the complex yin and yang like interaction of DNA repair and 




replicative stress versus oncogenesis, MYC also promotes the expression of DNA damage 
response proteins such as CHK1 and WRN helicase, both of which are required for MYC 
dependent cancer cell proliferation and survival16,17. Surprisingly, abolished ATR levels in 
mice with ATR seckel syndrome, completely prevented the development of MYC induced 
lymphomas16 indicating that replication stress resistance is necessary for MYC driven 
oncogenesis and that MYC is intrinsically boosting this process. In keeping with these 
findings, using a SHEP Tet 21/n inducible MYCN system, it was also shown that MYCN 
induces replication stress in NB cells. MYCN induction resulted in the phosphorylation of 
RPA, a marker for replication stress18,19, suggesting similar replicative stress control by both 
MYC and MYCN. Petroni et al. could show that overexpression of MYCN induces the DNA 
damage response and leads to the stabilization of p5319 and interestingly similar 
mechanisms were also described in zebrafish 20. In this MYCN driven model for NB, also used 
in this thesis, tumor penetrance was 20%, with evidence of dramatic loss of initiating tumor 
cells at week 5.5 and formation of full blown tumors at week 9. In tg(dβh:EGFP-MYCN; 
dβh:ALK F1174L) double transgenic fish, penetrance increases above 50%. More detailed 
analysis showed that MYCN overexpression induced adrenal sympathetic neuroblast 
hyperplasia, blocked chromaffin cell differentiation and ultimately triggered a 
developmentally timed apoptotic response20. It has been assumed that co-expression of 
activated ALK with MYCN provides pro-survival signals that block this apoptotic response and 
allowing continued expansion and oncogenic transformation of hyperplastic neuroblasts, 
thus promoting progression to NB20. We could show that overexpression of dβh:BRIP1 into 
the tg(dβh:EGFP-MYCN) transgenic background also enhanced the penetrance three-fold. 
My current working hypothesis is that increased BRIP1 expression will repress replicative 
stress induced DNA damage during the early phase of neuroblast hyperplasia. To investigate  
this we will perform more in depth DNA damage and replicative stress assays on the 
different stages of tumor formation in zebrafish and monitor how elevated BRIP1 levels 
impact on DNA damage levels.  
BRIP1, one protein, many functions 
While multiple functions have already been assigned to BRIP1 in relation to DNA damage 
signaling, DNA repair and protecting cells from replicative stress, it is assumed that further 




notice, although BRIP1 was initially found to be implicated in homologous recombinant (HR) 
pathway through binding with BRCA1, several other functions are assumed to act 
independent of BRCA1. At present, based on the work presented in this thesis, it is difficult 
to assign involvement of any of these functions in the BRIP1 mediated tumor acceleration 
process and possibly most or all functions could indeed be implicated. Here below I will 
discuss some of the BRIP1 functions in further detail and how they could impact on the 
observed accelerated tumor formations process. 
As an established Fanconi anemia gene, BRIP1 is implicated in the two major processes that 
are perturbed in the affected cells: interstrand crosslink (ICL) DNA repair and replication 
stability and integrity. ICLs represent a major challenge for DNA replication and transcription 
as they preclude DNA strand separation. It has been shown that cells depleted for BRIP1 are 
more sensitive for DNA cross-linking agents (mitomycin C, cisplatin)21,22, indicative for an 
involvement of BRIP1 in unraveling of ICLs. Indeed, processing of ICLs requires activation of 
the Fanconi anemia pathway and ubiquitination of FANCI and FANCD223. Subsequently, 
BRIP1 will be recruited to the ICL and will resolve this through binding with MLH122,24. In 
relation to replication fork stability, several recent proteomics studies have shown direct 
interaction of BRIP1 in stalled and/or collapsed forks25. 
BRIP1 has a DNA helicase domain and this function has been extensively studied in relation 
to unwinding and resolving so-called G-quadruplex DNA structures. As explained in more 
detail above, such G-quadruplexes are extremely stable structures sterically impeding DNA 
replication and thus posing a potential threat when not removed timely26. As such, one can 
imagine that depletion of BRIP1 protein in highly challenged initiating tumor cells can lead to 
increased unresolved G-quadruplexes thus leading to increased replication fork stalling and 
thus replicative stress. In addition, BRIP1 is also important to dissociate DNA:RNA hybrids (R-
loops) known to occur due to replication transcription conflicts27,28. Interestingly, even in the 
absence of agents that exogenously induce replication stress, BRIP1 helicase activity is 
important to maintain genome integrity. BRIP1 is involved in intra-S phase checkpoint 
signaling through interaction with TopBP1, allowing phosphorylation of CHK1 and RPA 
following replication stress29,30. Taken together, it is clear that unraveling the exact 
contribution of BRIP1 to the NB oncogenic phenotype will require dedicated further research 
using the appropriate assays. Also, I plan on a follow up study to demonstrate not only BRIP1 




driven tumor acceleration but also tumor dependency using a new generation inducible 
dβ(i)BRIP1 overexpression transgenic zebrafish. In a first step, the BRIP1 overexpression 
construct will be switched on in a MYCN background leading to a high NB tumor penetrance. 
In a second step when full blown tumors are observed, the overexpression (i)BRIP1 will be 
switched off and I hypothesize that upon loss of (i)BRIP1 in MYCN/BRIP1 double transgenic 
tumors, a regression of the already established NB tumors will be observed 
 
In relation to the interaction of BRIP1 with BRCA1, it is of interest that in this thesis we also 
show that BRCA1 is highly expressed in NB tumors. In addition to the well-established role of 
BRCA1 in DNA double strand break repair, recent studies indicate that this protein is also 
implicated in many other processes including replication stress and activation of the 
ATR/CHK1 pathway, control of R-loop mediated DNA damage31, facilitating phosphorylation 
of CHK1 upon sensing of ssDNA32and even acting as transcription factor amongst other 
controlling levels of the ribonucleotide reductase component RRM2 essential for DNA 
replication and DNA repair33. These findings, like for BRIP1, suggest that BRCA1 also acts as a 
cooperative oncogene in NB. Preliminary data from our lab and data from the Molenaar lab 
(personal communication) indeed support this hypothesis by in vitro data showing that NB 
cells depend on high BRCA1 levels for survival. To study this in vivo we overexpressed BRCA1 
in the MYCN zebrafish model but observed no tumor acceleration. However, as BRCA1 is not 
conserved in the zebrafish genome, the relevant functional context for BRCA1 operation may 
be lacking explaining the observed results. Further modeling therefore should be done in a 
mouse model or the newly described mouse neural crest derived NB model (Olsen et al. 
Oncogene, accepted).  
Finally, it has been reported that BRIP1 is a downstream target of FOXM134 and thus forms 
part of a broad DNA damage response network regulated by FOXM1. Indeed, upon lentiviral 
knockdown of FOXM1 in IMR-32 NB cells, we clearly observed an enrichment for DNA repair 
by gene set enrichment analysis (GSEA) and we could also confirm BRIP1 as a downstream 
target of FOXM1. In the second part of my thesis, I described the major impact of FOXM1 




hypothesize that this controls stem cells characteristics of aggressive NB cells by keeping the 
cell cycle and DNA repair mechanisms in check (paper 2). 
 
FOXM1 as master regulator of the DNA damage response 
 
The main function of the DREAM complex is to repress gene expression during quiescence 
(G0). When cells exit the G0 phase, FOXM1 and MYBL2 are recruited to promote mitotic 
gene expression thereby controlling proper DNA replication and avoiding excessive DNA 
damage35,36. Besides being a member of the DREAM complex, FOXM1 is also an integral 
component of the DNA damage checkpoint signaling network, driving the transcription of a 
diverse range of genes encoding for DNA damage sensors, signaling mediators and effectors 
for cell cycle checkpoints, cell death and senescence37. Using Chip-seq data, we could show 
that FOXM1 is a downstream target of MYCN, thus illustrating one mechanism through 
which MYCN can restrain replication stress and control the DNA repair pathway. Using the 
MYCN zebrafish NB model, I recently initiated FOXM1 targeted overexpression in order to 
monitor effects on accelerated tumor formation as a prelude to gain further insights into 
how FOXM1 and MYCN cooperate in NB oncogenesis.  
Sumoylation is an important posttranslational modification for the FOXM1 protein. 
Importantly, recent evidence showed that increased sumoylation of FOXM1 by SUMO2 
during M-phase specifically inhibits the negative regulatory domain of FOXM1, leading to an 
enhanced FOXM1 transcriptional activity. In response to treatment with DNA damaging 
agents such as epirubicin, or mitotic inhibitors, FOXM1 sumoylation was enhanced in MCF-7 
breast cancer cells38. In this respect, it has also been shown that sumoylation plays a critical 
role in the DNA damage response, as it has been linked to DNA repair through studies on the 
base excision repair pathway. Moreover, it was shown that SUMO2 (and SUMO1/3) 
accumulate at sites of double stranded breaks or replication fork stalling39,40. The close 
coordination between the processes of DNA repair and sumoylation has recently been 
confirmed by demonstrating that FOXM1 and many of its direct and indirect target genes, 
including BRCA1, BARD1 and RRM2, are posttranslationally regaled through so called sumo-
waves or group protein modifications.41. Interestingly, I modelled overexpression of 




dβh:SUMO2 into tg(dβh:MYCN-EGFP) zebrafish and indeed showed acceleration of NB onset 
(preliminary results), suggesting that sumoylation is an important process in NB 
development. 
 
Targeting BRIP1, FOXM1 and the DNA damage response as entry point for precision oncology 
for children suffering from high risk NB: towards a durable cure with fewer side effects 
 
Finding a new cure or strategy for the treatment of cancer patients, is probably the holy grail 
for every cancer researcher. Both BRIP1 and FOXM1 are promising therapeutical targets 
since drastic phenotypic effects are observed in NB cells upon knock down (paper 1 and 
paper 2). Currently, chemotherapy in combination with additional treatment (including bone 
marrow transplantation and immunotherapy) are still failing in roughly half of the high risk 
cases. Moreover, follow up studies of long term survivors are now showing increasingly the 
dramatic impact of the aggressive therapy schemes on their quality of life, not in the least 
through significant increase in the risk for therapy induced cancers later in life. Clearly, to 
cope with these urgent clinical needs, more potent, durable and targeted strategies are 
needed.   
Despite intensive screening, no specific compound targeting BRIP1 could be identified so far 
(Brosh lab, personal communication). Although direct inactivation of BRIP1 is therefore 
currently not possible, several indirect approaches can be pursued. In breast cancer, it was 
shown that BRIP1 is controlled by the E2F/retinoblastoma (RB1) pathway through a 
conserved E2F responsive site in the BRIP1 promotor and that BRIP1 could be repressed 
using dihydroxyvitamin D3 binding on this site
42. Also other therapeutic options targeting the 
E2F/RB1 pathway, such as the CDK4/6 inhibitor palbociclib, have been described. 
Interestingly, it has been shown in the past that NB cells are sensitive for this inhibitor43. 
Another option is through the stabilization of G-quadruplex structures. BRIP1 is 
indispensable for the unraveling of G4 structures26, and stabilizing these structures would 
induce replication stress in the cancer cells. Several G4 stabilizers have been described 
(telomestatin, TMPYP4 tosylate, pyridostatin, BRACO-19) and some of them, amongst others 




since G4 structures are mainly formed at the telomeres, using these compounds would also 
affect hTERT, which was recently identified as an important oncogene in NB 
development45,46. Stabilizing quadruplex structures could also be a strategy in the NB patient 
subgroup with ATRX deletions47, since ATRX null neuroprogenitor cells are hypersensitive to 
the G4 stabilizing ligand telomestatin48. Finally, as BRIP1, WRN and BLM function together in 
a complex for the unraveling of G-quadruplex structures26, an alternative approach for 
targeting BRIP1, would be through the use of the WRN helicase inhibitor (NSC 617145). As 
such, inhibiting WRN would indirectly also affect BRIP1 function.  
In contrast to BRIP1, several compounds have been described targeting FOXM1. Siomycin A 
and thiostreptin inhibit the transcriptional activity and the expression of FOXM1 through 
acting as proteasome inhibitors49. Indeed, we could observe a downregulation of FOXM1 
upon addition of Siomycin A in the NB cell line N206, however only starting 72h after 
addition (paper 3). In gastroenteropancreatic neuroendocrine tumors slightly synergistic 
effects were observed upon addition of Siomycin A and cisplatin, however, we could not 
confirm this synergistic effect in NB cells50. Siomycin A is a promiscuous molecule with 
potent off-target effects, most notably inhibition of the 20S proteasome, therefore also 
targeting several other proteins, possibly explaining our results. 
By performing a library screen of 54211 small molecules, a small molecule inhibitor of 
FOXM1 (FDI-6) was discovered in the group of Balasubramanian51. FDI-6 binds directly to 
FOXM1 and displaces FOXM1 from its genomic targets. The authors performed 
transcriptome profiling after 0, 3, 6 and 9 hours of FDI-6 treatment and could clearly 
demonstrate downregulation of FOXM1 target genes51. Upon addition of FDI-6 to IMR-32 NB 
cells, we could indeed confirm downregulation of FOXM1 target genes 6h after 
administration. However, 24h after administration, to our surprise we consistently observed 
upregulation of the FOXM1 target genes. To exclude that this loss off FDI-6 efficacy is due to 
compound degradation, we administrated the drug every 12h to the cells, however, this did 
not result in a sustained downregulation of FOXM1 activity, indicating that compound 
degradation is not the reason for the observed phenotype (data not shown). These results 
precluded further studies using this compound. The reason for the short lived response of 
the cells to the drug are unclear. One could imagine that the cells respond through classical 
drug resistance mechanisms such as activation of drug efflux pumps or the sequestering of 




the drug into cellular vesicles that are then eliminated by exocytosis52 but one would think 
that such mechanism requires more time to be installed. Alternatively, cells may be strongly 
dependent on FOXM1 activity and undergo fast pathway rewiring that leads to reactivation 
of FOXM1 activity through an as yet unknown mechanism. In any case, given the strong 
focus of the research community on FOXM153 and the drug being available for several years 
it is indeed disturbing that no follow up studies have been reported, neither by the 
Balasubramanian lab nor by other labs.  
Fortunately, the activity of FOXM1 is fine-tuned by several post-translational modifications, 
thus offering alternative opportunities for drugging. Phosphorylation of FOXM1 by phospho-
like kinase 1 (PLK1) at the G2/M phase results in the activation of FOXM1 activity and the 
expression of key mitotic regulators54. PLK1 is only expressed in dividing cells and to a much 
lesser extent than cancer cells thus offering a therapeutic window. Several compounds 
targeting PLK1 have been described and many of them compete with ATP for the substrate 
binding site55 including volasertib (BI6727). Several preclinical experiments have 
demonstrated that volasertib is potent in inducing tumor regression. Therefore, this agent 
has recently been awarded the “Breakthrough Therapy Status” by the FDA for its significant 
benefit in treating AML patients55. Interestingly, recently it was shown that PLK1 inhibitors 
induce reduced proliferation, cell cycle arrest and cell death in NB cells56, indicating that this 
is an important pathway. Another indirect FOXM1 drugging approach is through targeting 
maternal embryonic leucine zipper kinase (MELK). FOXM1 forms a protein complex with 
MELK and resulting in the phosphorylation and activation of FOXM157. While several studies 
have been conducted with the MELK inhibitor OTS16758, experts in the field strongly doubt 
the on target specificity of OTS167 (Bollen lab, personal communication) precluding the use 
of this drug for pre-clinical studies. Interestingly, through a large kinase inhibitor screen, a 
novel MELK inhibitor, MELK-T1 was recently identified59, opening new perspectives for 
specific inhibition of MELK dependent FOXM1 activation. The posttranslational sumoylation 
of FOXM1 offers yet another therapeutic opportunity. A compound library screen resulted in 
the identification of compound 21 that decreases sumoylation with 85%60. 
Besides targeting BRIP1 and FOXM1, further therapeutic approaches can also be pursued. In 
this thesis we show that NB cells experience replication stress and that ATR/CHK1 signaling 




enhance replication stress and that target the ATR/CHK1 axis could also be of great interest 
for treating NB patients. Several novel drugs targeting CHK1 (LY2606368, CCT245737) and 
ATR (ATR-101, VX-970) already entered clinical trials, opening perspectives for treatment of 
NB patients. Of interest, an alternative approach to inhibit CHK1 is to target WEE1 (MK-
1775), a kinase that phosphorylates cell cycle regulators CDK1 and CDK2. Inhibition of WEE-1 
leads to enhanced CDK1/2 activity causing cells in S phase to enter mitosis prematurely 
before DNA replication is complete61 causing mitotic catastrophy. Interestingly, the 
combination of WEE1 and CHK1 inhibitors has been tested in NB cells and indeed resulted in 
a synergistic effect61,62. 
 
In this thesis we show that FOXM1 is a downstream target of MYCN, presenting yet another 
therapeutic option. Given the impact of MYCN in NB biology, MYCN is amplified in around 
20% of the tumors63, an enormous effort has already been invested in the identification of 
compounds that target MYCN. Hence, direct inhibition of MYCN in vivo is cumbersome, since 
MYC proteins are composed of two extended alpha-helices with no obvious surfaces for 
small molecule binding. However, several indirect approaches can be pursued, BET family 
adaptor proteins localize to MYC promotors , and therefore targeting BET also indirectly 
influences MYCN activity. Several BET inhibitors have been described, amongst others JQ1 
and OTX015. In NB cell lines, responses to JQ1 inhibition varied from highly sensitive to 
resistant64, with amplification of MYCN as a top predictive marker of response to JQ1 
treatment. Also OTX015 has been shown to have therapeutic effects against preclinical 
MYCN driven NB models65.  
 
Proteins that prevent dephosphorylation at T58 stabilize MYCN, which may be the case with 
AURKA in NB66. Interestingly, increased expression of AURKA is found in MYCN amplified NB, 
mediated potentially by MYCN itself67. Therefore, promoting dissociation of the AURKA-
MYCN complex, which results in rapid proteosomal degradation of MYCN, represent another 
strategy to target oncogenic stabilization of MYCN. Certain AURKA inhibitors, such as 
MLN8237, induce a particular conformational change in the kinase that actively reinitiates 
MYCN degradation through this mechanism68. MLN8237 was identified as a promising agent 




for NB but has not displayed robust antitumor activity in early-phase pediatric studies, 














Figure 7.1: Schematic overview of the MYCN-FOXM1-BRIP1(17q) axis and possible therapeutic 
interventions.  
 
BRIP1 and 17q gain: one done, more to go? 
 
I consider the identification of BRIP1 as a cooperative oncogene for MYCN driven tumor 
formation as a major novel finding in NB biology offering novel unexpected opportunities for 
drugging. While my data convincingly show the importance of BRIP1 as putative effector of 




important in NB. Which would explain the apparent tremendous high selective pressure 
towards retaining chromosome 17 imbalances causing 17q gain as an almost invariable 
feature of the high risk NB genome. Most notably, in a MYCN driven NB mouse model, gain 
of chromosome 11 (which is syntenic to chromosome 17q in human) is also observed in 
about 25% of the tumors71, showing that this process is conserved. A further search for 
dosage sensitive genes on 17q is certainly warranted. First, the involved large segment 
(17q23-qter) is large, suggesting that in addition to BRIP1 at least one additional gene, 
possibly located much more distal towards the 17q telomere could be implicated. Second, 
based on a time course analysis of gene expression (1,2 and 6 weeks after birth) in the 
superior cervical ganglia and the celiac ganglia of Th-MYCN and wild type mice during several 
stages of NB development 72, several downstream targets of FOXM1 (TOP2A, BIRC5, TLK1…) 
were found amongst the top upregulated genes and in keeping with being FOXM1 targets 
involved in DNA metabolism and DNA repair (Durinck et al, in preparation). These data are in 
keeping with the presently proposed hypothesis in the host lab that gain of chromosome 
17q, through combined dosage effects of multiple genes, drives a cellular state characterized 
by replicative stress resistance and highly efficient DNA repair. Recent work from the 
Gilbertson team indeed demonstrated such a phenomenon to be active in the brain tumor 
ependymoma. Genome wide copy number alterations are also frequently observed in these 
tumors and to sift through the many putative candidates the team used a large in vivo 
screen of 84 candidate oncogenes and 39 candidate tumor suppressor genes (TSG) located in 
28 copy number aberrations. As such, they identified eight new oncogenes and ten new 
tumor suppressor genes, all involved in similar cell functions7. This study thus indeed 
illustrates that multiple dosage sensitive genes residing in the commonly affected 
chromosome regions can be actively involved in tumor initiation and/or progression through 
installing a so-called cellular state driven through one or more altered cellular functions7.  
Zebrafish as a model to study NB tumor acceleration and validation of candidate cooperative 
oncogenes 
The MYCN driven zebrafish NB model was demonstrated to be useful for testing the effect of 
cooperative oncogenes on tumor acceleration as illustrated by the pioneering work of the 
Look lab for mutant ALK and confirming earlier observations in mouse. More recently, NF1 
loss-of-function mutations were also shown to accelerate MYCN driven tumor formation in 




zebrafish73. My study adds yet another gene to the list of those impacting on MYCN driven 
tumor onset and penetrance and thus further reinforces the relevance of this animal model 
for these experiments. Indeed, many additional genes are now under study in the host lab 
for leukemia and NB, all in the slip stream of my initial BRIP1 work. Further, the zebrafish 
cancer core of the host lab is rapidly expanding and exploring further novel paths including 
genomic profiling methods of tumor cells (including single cells) as well as using zebrafish for 
drug testing, amongst others. 
Optimizing of RT-qPCR normalization in zebrafish studies 
 
Much of my early PhD work was focused on introducing modeling of cancer in zebrafish in 
the Ghent zebrafish lab, following my stay in the Look lab at the Dana Farber Cancer Institute 
(Boston, USA). Given the worldwide recognized expertise of the Center for Medical Genetics 
in Ghent in normalization strategies for qPCR based gene expression studies74,75, I decided to 
exploit this know how in the context of the zebrafish model system. Indeed, gene expression 
analysis is increasingly important in many fields of biological research and RT-qPCR is 
currently frequently used given its practical simplicity and processing speed. However, 
different critical factors can influence the outcome of the RT-qPCR studies and these have to 
be applied properly to obtain biologically meaningful results. Since under specific biological 
conditions the frequently used reference genes in zebrafish did not perform up to standard, 
we applied a new normalization strategy based on expressed repeat elements (paper 4). 
Starting from a database encompassing all repetitive elements expressed in zebrafish, we 
selected 10 EREs for further validation. Comparing the 10 most frequently used reference 
genes in zebrafish with the 10 selected EREs, we could convincingly show that in almost 
every situation the EREs perform much better than the standard reference genes. Especially 
in challenging situations (such as time series or comparing different tissues) the EREs were 
more stably expressed resulting in biologically more reliable and robust results. This work 
has broader application possibilities as we suggest that this strategy can be applied to other 
model organisms as well. Indeed, using a similar workflow we could identify and validate 





General conclusions and perspectives 
 
When I started on the BRIP1 modeling in NB, ALK was the only gene known to drive 
accelerated tumor formation in the MYCN targeted overexpressing zebrafish NB model (see 
above). Selecting zebrafish at the start of this work therefore was a major challenge but 
fortunately, in the end, turned out to be successful. My pioneering work in the lab has now 
evolved into a fully equipped and operational zebrafish cancer modeling unit currently 
actively exploring the mode of action for many novel candidate genes. Despite these 
successes important challenges remain. Most notably, MYCN amplification only represents 
about half of all high risk NBs. Most of the remaining half carry a large 11q deletion and 17q 
gain with no subset specific associated mutations. This currently precludes the modeling of 
this important group of tumors with poor prognosis. Recent work in the host lab has led to 
the identification of several 11q candidates following the same bioinformatics approach 
applied here. Therefore, yet another major breakthrough may be ahead of us as modeling 
the high risk NB without MCYN amplification is considered as one of the major aims for 
ongoing NB research.  
Further, as indicated, BRIP1 function in relation to NB tumor formation needs further 
investigation and also direct drugging of BRIP1 would possibly add yet another drug to the 
currently rapidly growing repertoire of compounds for precision treatment for NB. Further, 
also the additional 17q candidate cooperative genes need further modeling and 
investigation as they themselves can also represent novel drug targets. Then, a further 
challenge is to test the optimal combination therapies as single compound treatment 
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Science may set limits to knowledge, 
but should not set limits to imagination 












Neuroblastoma is a neural crest derived childhood tumor. The majority of these tumors arise 
in the adrenal gland and the sympathetic ganglia of infants and young children. These 
tumors display a broad spectrum of clinical heterogeneity ranging from spontaneous 
regression to aggressive metastatic disease. Especially for the latter group of patients, no 
adequate therapy is available yet and survival chances remain very poor. Advanced targeted 
treatment strategies may provide solutions for this problem, however, in order to benefit 
from these personalized treatments, it is of utmost importance to identify molecular targets. 
So far, only a limited number of genes have been identified that play a role in neuroblastoma 
oncogenesis, with mutations in ALK being the most prevalent and only occurring in 10% of 
the cases. In contrast to the paucity of mutations, copy number aberrations are frequently 
observed in neuroblastoma tumors, with gain of chromosome 17q being the most common 
abnormality detected and correlated with poor patient outcome. A better knowledge of 
which genes on 17q are important in neuroblastoma development can offer novel 
therapeutic targets and options for design of novel therapies.  
 
The first goal of my thesis was to follow-up on an initial bio-informatics approach intended 
to identify candidate 17q oncogenes. With this strategy, BRIP1 located on chromosome 
17q23 was identified as a cooperative oncogene in neuroblastoma development. High 
expression of BRIP1 correlated with poor patient outcome and stable BRIP1 knock-down in 
neuroblastoma cell lines significantly reduced cell viability and colony forming capacity. 
Moreover, overexpression of dβh-BRIP1 into the transgenic tg(dβh-EGFP-MYCN) zebrafish 
resulted in acceleration of neuroblastoma onset and tripled the penetrance compared to 
transgenic tg(dβh-EGFP-MYCN) zebrafish. Finally, we could show that overexpression of 
BRIP1 is indispensable to control replicative stress experienced by the neuroblastoma tumor 
genome and that BRIP1 creates a cellular state what we call “replication stress resistance”. 
 
In the second part, we wanted to explore whether an ESC derived expression signature could 




resistance. An ESC miRNA signature could be identified that allows to discriminate patients 
with worse survival in the global cohort of neuroblastoma patients, but most interestingly 
also in a subset of high-risk tumors, i.e. stage 4 tumors without MYCN amplification. Analysis 
of the protein coding genes that are correlated with the ESC miRNA signature score in 
neuroblastoma patients, pointed at a FOXM1 driven cell cycle and DNA repair activation in 
therapy resistant tumors. Interestingly, these findings can reveal new therapeutic 
approaches for tumors where current treatment regimens fail.  
In the last part of this thesis, we identified new reference genes for the normalization of RT-
qPCR experiments in zebrafish. Proper selection of reference genes is a critical step to obtain 
biologically meaningful results. Starting from a database encompassing all repetitive 
elements expressed in zebrafish, we selected 10 expressed repeat elements (ERE’s) for 
further validation. Comparing the 10 most frequently used reference genes in zebrafish with 
the 10 selected EREs, we could convincingly show that in almost every situation, our 








Neuroblastoom is een kinderkanker met een neuronale oorsprong die voornamelijk optreedt 
in de bijnieren en de sympathische ganglia van baby’s en jonge kinderen. Deze tumoren 
vertonen een zeer gevarieerd klinisch beeld dat kan gaan van spontane regressie tot zeer 
agressieve tumoren die uitzaaien. Vooral voor die laatste groep van patiënten zijn er tot op 
heden geen efficiënte therapieën beschikbaar en blijven de overlevingskansen laag. 
Geavanceerde gerichte therapeutische strategieën kunnen mogelijks een oplossing bieden 
voor dit probleem. Om van deze gepersonaliseerde therapieën gebruik te kunnen maken is 
het echter een vereiste dat er moleculaire doelwitten geïdentificeerd worden. Tot op 
vandaag is er slechts een beperkt aantal genen geïdentificeerd met een rol in neuroblastoom 
ontwikkeling, waarbij mutaties in het ALK gen het meest worden waargenomen en dat in 
slechts 10% van de neuroblastoom patiënten. In tegenstelling tot het beperkt aantal 
mutaties worden in neuroblastoom zeer frequent copynumbervariaties waargenomen, 
waarbij winst van chromosoom 17q, dat gecorreleerd is met een slechte overleving voor de 
patiënten, de frequentste kopie nummer afwijking is. Een beter inzicht in welke genen op 
17q belangrijk zijn voor de ontwikkeling van neuroblastoom kan helpen voor de identificatie 
van nieuwe doelwitgenen en therapieën.  
 
Het eerste doel van mijn thesis was het verder onderzoeken van 17q oncogenen die in een 
eerdere bio-informatica analyse waren geïdentificeerd als potentieel kandidaat genen. 
BRIP1, gelokaliseerd op chromosoom 17q23, werd geïdentificeerd als een belangrijk 
coöperatief oncogen in de ontwikkeling van neuroblastoom. Hoge expressie van BRIP1 is 
gecorreleerd met een slechte overleving van neuroblastoom patiënten en stabiele 
neerregulatie van BRIP1 in neuroblastoom cellijnen resulteerde in een verminderde cel 
viabiliteit en kolonie vormende capaciteit. Daarnaast resulteerde overexpressie van dβh-
BRIP1 in de transgene zebravislijn tg(dβh:EGFP-MYCN) in een versnelling van neuroblastoom 
ontwikkeling en werd ook de penetrantie voor tumorvorming verdrievoudigd. Finaal konden 
we aantonen dat BRIP1 noodzakelijk is voor het controleren van replicatie stress in het 
neuroblastoom tumor genoom en dat BRIP1 een cellulaire toestand induceert die wij 




In het tweede deel werd nagaan of een signatuur afkomstig van embryonale stamcellen een 
stamcel fenotype kan bepalen in neuroblastoom cellen die resistent zijn aan therapie. We 
konden een ESC miRNA signatuur bepalen die in staat was om neuroblastoom patiënten met 
een slechte prognose te identificeren. Bovendien, kon deze signatuur ook gebruikt worden 
voor het bepalen van ultra hoog risico patiënten in de hoog risico neuroblastoom subgroep, 
namelijk de stadium 4 patiënten zonder MYCN amplificatie. Analyse van de eiwit coderende 
genen gecorreleerd met de ESC miRNA signatuur toonden aan dat FOXM1 belangrijk was 
voor het aansturen van deze signatuur. Deze bevindingen kunnen leiden tot nieuwe 
therapeutische strategieën voor tumoren waar de huidige behandelingsschema’s falen.  
In het laatste deel van deze thesis werden nieuwe referentie genen voor de normalisatie van 
RT-qPCR experimenten in zebravis geïdentificeerd. Correcte selectie van referentie genen is 
belangrijk om biologisch relevante resultaten te verkrijgen. Hiervoor zijn we gestart van een 
databank waarin alle repetitieve elementen die in zebravis tot expressie worden gebracht 
zijn gebundeld en vervolgens werden uit deze databank 10 repeat element geselecteerd 
voor verdere validatie. Wanneer we de 10 meest gebruikte referentie genen gebruikt in 
zebravis, vergeleken met onze repeat elementen, konden we zeer overtuigend aantonen dat 
in bijna iedere situatie onze repeat elementen veel beter presteerden dan de standaard 
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